Immuron Limited (IMRN) 20-F 9 Sep 22 2022 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Jun. 30, 2022 shares
Document Information Line Items
Entity Registrant Name	IMMURON LIMITED
Trading Symbol	IMRN
Document Type	20-F
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding	227,798,346
Amendment Flag	false
Entity Central Index Key	0001660046
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	000-38104
Entity Incorporation, State or Country Code	C3
Entity Address, Address Line One	Level 3, 62 Lygon Street
Entity Address, City or Town	Carlton South
Entity Address, Postal Zip Code	3053
Entity Address, Country	AU
Title of 12(b) Security	American Depositary Shares, each representing 40 Ordinary Shares
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Accounting Standard	International Financial Reporting Standards
Auditor Firm ID	2233
Auditor Name	GRANT THORNTON AUDIT PTY LTD
Auditor Location	Melbourne, Australia
Business Contact
Document Information Line Items
Entity Address, Address Line One	Level 3, 62 Lygon Street
Entity Address, City or Town	Carlton South
Entity Address, Postal Zip Code	3053
Entity Address, Country	AU
Contact Personnel Name	Mr. Steven Lydeamore
City Area Code	61
Local Phone Number	3 9822 7735

Consolidated Statement of Profi

Consolidated Statement of Profit or Loss and Other Comprehensive Income	12 Months Ended
	Jun. 30, 2022 AUD ($)	Jun. 30, 2022 $ / shares	Jun. 30, 2021 AUD ($)	Jun. 30, 2021 $ / shares	Jun. 30, 2020 AUD ($)	Jun. 30, 2020 $ / shares
Profit or loss [abstract]
Revenue from contracts with customers	$ 765,193		$ 145,776		$ 2,518,566
Cost of Goods Sold	(241,691)		(51,071)		(688,836)
Gross Profit	523,502		94,705		1,829,730
Other Income	957,725		617,110		473,674
Net foreign exchange gains/(losses)	247,558		(582,528)		11,335
Net impairment losses			(759,765)
Expenses
General and administrative expenses	(3,524,388)		(6,094,692)		(3,170,078)
Research and development expenses	(657,715)		(1,367,054)		(1,178,685)
Selling and marketing expenses	(416,537)		(287,684)		(871,551)
Operating loss	(2,869,855)		(8,379,908)		(2,905,575)
Finance income	21,785		9,204
Finance expenses	(6,184)		(13,761)		(21,631)
Finance costs - net	15,601		(4,557)		(21,631)
Loss Before Income Tax	(2,854,254)		(8,384,465)		(2,927,206)
Income Tax Expense
Loss for the Period	(2,854,254)		(8,384,465)		(2,927,206)
Items that may be reclassified to profit or loss:
Exchange differences on translation of foreign operations	6,708		(14,953)		102,938
Total Comprehensive Loss for the Period	$ (2,847,546)		$ (8,399,418)		$ (2,824,268)
Basic/Diluted Loss per Share (in cents per share) (in Dollars per share) | $ / shares		$ (1.25)		$ (3.79)		$ (1.66)

Consolidated Statement of Pro_2

Consolidated Statement of Profit or Loss and Other Comprehensive Income (Parentheticals) - $ / shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Profit or loss [abstract]
Basic/Diluted Loss per Share (in cents per share)	$ (1.25)	$ (3.79)	$ (1.66)

Consolidated Statement of Finan

Consolidated Statement of Financial Position	Jun. 30, 2022 AUD ($)	Jun. 30, 2021 AUD ($)
Current Assets
Cash and cash equivalents	$ 22,110,278	$ 25,047,281
Trade and other receivables	662,896	334,707
Inventories	326,578	292,532
Other current assets	572,400	78,258
Total Current Assets	23,672,152	25,752,778
Non-Current Assets
Property, plant and equipment	226,736	33,741
Inventories	956,936	1,266,587
Total Non-Current Assets	1,183,672	1,300,328
TOTAL ASSETS	24,855,824	27,053,106
Current Liabilities
Trade and other payables	1,160,893	758,494
Provision for sales returns	95,931	213,024
Employee benefit obligations	211,776	129,837
Other current liabilities	34,376	20,498
Total Current Liabilities	1,502,976	1,121,853
Non-Current Liabilities
Employee benefit obligations	36	36,196
Other non-current liabilities	175,411
Total Non-Current Liabilities	175,447	36,196
TOTAL LIABILITIES	1,678,423	1,158,049
NET ASSETS	23,177,401	25,895,057
EQUITY
Issued capital	88,436,263	88,361,303
Reserves	3,166,419	3,466,642
Accumulated losses	(68,425,281)	(65,932,888)
TOTAL EQUITY	$ 23,177,401	$ 25,895,057

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - AUD ($)	Issued Capital	Reserves	Accumulated Losses	Total
Balance at Jun. 30, 2019	$ 60,289,875	$ 4,300,319	$ (57,240,537)	$ 7,349,657
Loss after income tax expense for the year			(2,927,206)	(2,927,206)
Other comprehensive income for the period		102,938		102,938
Total comprehensive loss for the period		102,938	(2,927,206)	(2,824,268)
Shares issued, net of costs	1,652,436			1,652,436
Options/warrants issued/expensed	484,680	(484,680)
Options/warrants lapsed/expired		(2,251,320)	2,251,320
Remeasurement of options issued in prior period		(607,000)		(607,000)
Share-based payment expenses		73,088		73,088
Balance at Jun. 30, 2020	62,426,991	1,133,345	(57,916,423)	5,643,913
Loss after income tax expense for the year			(8,384,465)	(8,384,465)
Other comprehensive income for the period		(14,953)		(14,953)
Total comprehensive loss for the period		(14,953)	(8,384,465)	(8,399,418)
Shares issued, net of costs	24,386,005			24,386,005
Options/warrants issued/expensed		3,003,060		3,003,060
Options/warrants exercised	1,329,307	(213,722)		1,115,585
Options/warrants forfeited		(368,000)	368,000
Shares issued to directors	145,912			145,912
Transfer to share capital	73,088	(73,088)
Balance at Jun. 30, 2021	88,361,303	3,466,642	(65,932,888)	25,895,057
Loss after income tax expense for the year			(2,854,254)	(2,854,254)
Other comprehensive income for the period		6,708		6,708
Total comprehensive loss for the period		6,708	(2,854,254)	(2,847,546)
Shares issued, net of costs	74,960			74,960
Options/warrants issued/expensed		54,930		54,930
Options/warrants forfeited		(361,861)	361,861
Balance at Jun. 30, 2022	$ 88,436,263	$ 3,166,419	$ (68,425,281)	$ 23,177,401

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Cash flows Related to Operating Activities
Receipts from customers	$ 696,603	$ 192,185	$ 2,914,614
Payments to suppliers and employees	(4,629,139)	(4,865,633)	(6,748,674)
Australian R&D tax incentive refund	306,154	358,280	531,828
Government grants and other grants received	478,589	236,421	154,904
Net Cash Flows Used In Operating Activities	(3,147,793)	(4,078,747)	(3,147,328)
Cash Flows Related to Investing Activities
Payment for purchases of plant and equipment	(10,048)	(6,630)	(864)
Interest received	21,785	9,204
Net Cash Flows From/(Used In) Investing Activities	11,737	2,574	(864)
Cash Flows Related to Financing Activities
Proceeds from issues of securities		29,281,421	1,957,164
Capital raising costs		(2,746,871)	(374,728)
Proceeds from borrowings		212,794
Repayment of borrowings		(212,794)	(366,655)
Principal elements of lease payments	(36,264)	(40,607)	(41,390)
Interest and other costs of finance paid	(6,184)	(13,761)	(17,439)
Net Cash Flows (Used In)/From Financing Activities	(42,448)	26,480,182	1,156,952
Net (decrease)/increase in cash and cash equivalents	(3,178,504)	22,404,009	(1,991,240)
Cash and cash equivalents at the beginning of the year	25,047,281	3,250,468	5,119,887
Effects of exchange rate changes on cash and cash equivalents	241,501	(607,196)	121,821
Cash and Cash Equivalents at the End of the Year	$ 22,110,278	$ 25,047,281	$ 3,250,468

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2022
Disclosure Of Significant Accounting Policies Text Block Abstract
Summary of Significant Accounting Policies	Note 1. Summary of Significant Accounting Policies Corporate Information The consolidated financial report of Immuron Limited (“the Company”) for the year ended June 30, 2022, 2021 and 2020 was authorized for issue in accordance with a resolution of the Directors on September 9, 2022. Immuron Limited is a listed public company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange (“ASX”) and The NASDAQ Capital Market (“NASDAQ”). The Group’s principal activity is oral immunotherapy research and development and product sales focused on bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infectious diseases. Product sales comprise Travelan which is indicated to reduce the risk of contracting travelers’ diarrhea and Protectyn an OTC immune supplement for GI tract and liver health. (a) Basis of preparation These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board and the Corporations Act 2001 (i) Compliance with IFRS The consolidated financial statements of the Immuron Limited group also comply with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). (ii) Historical cost convention The financial statements have been prepared on a historical cost basis. (iii) Significant estimates and judgements Going concern The group is in a position to meet future commitments in the current business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress its research and development programs for at least the next 12 months. The annual report has been prepared on a going concern basis. Accordingly, the annual report does not include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of liabilities that might be necessary should the group not continue as a going concern. COVID-19 Judgement has been exercised in considering the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the group based on known information. This consideration extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the group operates. Sales of Travelan have significantly dropped from March 2020 and as at reporting date sales has started to recover. This note provides a list of the significant accounting policies adopted in the preparation of these consolidated financial statements to the extent they have not already been disclosed in the other notes above. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial statements are for the group consisting of Immuron Limited and its subsidiaries. (iv) New standards and interpretations not yet adopted There are no standards that are not yet effective and that would be expected to have a material impact on the Company in the current or future reporting years and on foreseeable future transactions. Summary of significant accounting policies The following is a summary of the material accounting policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently applied, unless otherwise stated. (b) Principles of consolidation (i) Subsidiaries Subsidiaries are all entities (including structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from the date that control ceases. The acquisition method of accounting is used to account for business combinations by the group. Intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group. (c) Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. This has been identified as the executive management team consisting of the CEO and COO. (d) Foreign currency translation (i) Functional and presentation currency Items included in the financial statements of each of the group’s entities are measured using the currency of the primary economic environment in which the entity operates (‘the functional currency’). The consolidated financial statements are presented in Australian dollar (“A$” or “$”), which is Immuron Limited’s functional and presentation currency. (ii) Transactions and balances Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss. Foreign exchange gains and losses that relate to borrowings are presented in the consolidated statement of profit or loss and other comprehensive income, within finance costs. All other foreign exchange gains and losses are presented in the consolidated statement of profit or loss and other comprehensive income on a net basis within other gains/(losses). Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair value through other comprehensive income are recognized in other comprehensive income. (iii) Group companies The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows: ● assets and liabilities for each consolidated balance sheet presented are translated at the closing rate at the date of that consolidated balance sheet; ● income and expenses for each consolidated statement of profit or loss and consolidated statement of profit or loss and other comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and ● all resulting exchange differences are recognized in other comprehensive income. On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or loss on sale. (e) Income and revenue recognition (i) Sale of hyperimmune products Revenue arises mainly from the sale hyperimmune products. To determine whether to recognize revenue, the group follows the process of identifying the contract with a customer, identifying the performance obligations, determining the transaction price, allocating the transaction price to the performance obligations and recognizing revenue when performance obligations are satisfied. Revenue from the sale of hyperimmune products is recognized at a point in time when or as the group transfers control of the assets to the customer upon delivery of the products. There is no significant cost to obtain the contract. However, there is variable consideration due to rebates, discounts and refunds. The variable amount of consideration is allocated entirely to the distinct good that is consistent with the amount of consideration to which the group expects to be entitled in exchange for transferring the promised goods to the customer. The group offers rebates of up to 10% to some loyal wholesalers in Australia. During the financial year 2022, to improve the relatively low sales during the previous financial year, the group initiated periodic discounts of up to 50% for Protectyn products purchased by the end customers via wholesalers. There are no warranties. Returns and refunds are provided where this is outlined in a customer agreement. The group does not have a formal policy in place relating to stock returns. In cases where we have a contract in place with a distributor, and that contract includes a stock return policy, we will adhere to the policy listed in the contract. For all other distributors, stock returns are negotiated on a case-by-case basis. The exception to this is where stock is short dated to within 3 months. In this case we will offer replacement stock or a refund. (ii) Financing components The group does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the group does not adjust any of the transaction prices for the time value of money. (ii) R&D grants from HJF and MTEC The group’s other grant income is recognized when compliance with the conditions attached to the grant have been determined and the group has ascertained the grant will be received and the amount can be reliably measured. For the year ended 30 June 2022, the group has recognized $306,595 (2021: $74,821) R&D grant from the Henry M Jackson Foundation (“HJF”) and $369,045 (2021: Nil (f) Government grants Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received, and the group will comply with all attached conditions. Other income amounts are recognized when it has been established that the conditions of the government grants have been met and that the expected amount can be reliably measured. Government grants are recognized in profit or loss on a systematic basis over the periods in which the Group recognizes as expenses the related costs for which the grants are intended to compensate. Accrued receivables These amounts primarily comprise receivables from the Australian Taxation Office in relation to the R&D tax incentive. (g) Income tax The income tax expense or credit for the period is the tax payable on the current period’s taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. Current and deferred tax is recognized in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively. As per IFRIC 23 Uncertainty over Income Tax Treatments, where it is probable, the group has determined tax balances consistently with the tax treatment used or planned to be used in its income tax filings. Where the group has determined that it is not probable that the taxation authority will accept an uncertain tax treatment, the most likely amount or the expected value has been used in determining taxable balances (depending on which method is expected to better predict the resolution of the uncertainty). (i) Leases Leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the group. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: ● fixed payments (including in-substance fixed payments), less any lease incentives receivable ● variable lease payment that are based on an index or a rate ● amounts expected to be payable by the lessee under residual value guarantees ● the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and ● payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be determined, or the group’s incremental borrowing rate. Right-of-use assets are measured at cost comprising the following: ● the amount of the initial measurement of lease liability ● any lease payments made at or before the commencement date, less any lease incentives received ● any initial direct costs, and ● restoration costs. Payments associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT-equipment and small items of office furniture. (j) Impairment of assets An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period. (k) Cash and cash equivalents For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities in the consolidated balance sheet. (l) Trade receivables Trade receivables are recognized initially at fair value and subsequently measured at amortised cost using the effective interest method, less loss allowance. The group applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. To measure the expected credit losses, trade receivables assets have been grouped based on shared credit risk characteristics and the days past due. The expected loss rates are based on the payment profiles of sales over a period of 60 months before June 30, 2022 and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. (i) Classification as trade receivables Trade receivables are amounts due from customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within 30 days and therefore are all classified as current. Trade receivables are recognized initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognized at fair value. The group holds the trade receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method. Details about the group’s impairment policies and the calculation of the loss allowance are provided below. (iii) Fair value of trade and other receivables Due to the short-term nature of the current receivables, their carrying amount is considered to be the same as their fair value. (iv) Impairment for financial instruments The Group’s risk management is predominantly controlled by the Board. The Board monitors the Group’s financial risk management policies and exposures and approves substantial financial transactions. It also reviews the effectiveness of internal controls relating to market risk, credit risk and liquidity risk. The Board is responsible for overseeing the establishment and implementation of the risk management system, and reviews and assesses the effectiveness of the Company’s implementation of that system on a regular basis. The Board and Senior Management identify the general areas of risk and their impact on the activities of the Company, with Management performing a regular review of: Ø the major risks that occur within the business; the degree of risk involved; Ø the current approach to managing the risk; and Ø if appropriate, determine: ○ any inadequacies of the current approach; and ○ possible new approaches that more efficiently and effectively address the risk. Management report risks identified to the Board through the monthly Operations Report. The Company seeks to ensure that its exposure to undue risk which is likely to impact its financial performance, continued growth and survival is minimized in a cost effective manner. (m) Inventories Raw materials and stores, work in progress and finished goods Raw materials and stores, work in progress and finished goods are stated at the lower of cost and net realizable value. Cost comprises direct materials, direct labour and an appropriate proportion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Costs are assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased inventory are determined after deducting rebates and discounts. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. (n) Investments and other financial assets (i) Classification The group classifies its financial assets in the following measurement categories: ● those to be measured subsequently at fair value (either through other comprehensive income or through profit or loss); and ● those to be measured at amortized cost. The classification depends on the group’s business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses will either be recorded in profit or loss and other comprehensive income. For investments in equity instruments that are not held for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI). (ii) Recognition and derecognition Regular way purchases and sales of financial assets are recognized on trade-date, the date on which the group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has transferred substantially all the risks and rewards of ownership. (iii) Measurement At initial recognition, the group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss. (v) Income recognition - Interest income Interest income is recognized using the effective interest method. When a receivable is impaired, the group reduces the carrying amount to its recoverable amount, being the estimated future cash flow discounted at the original effective interest rate of the instrument, and continues unwinding the discount as interest income. Interest income on impaired loans is recognized using the original effective interest rate. (o) Property, plant and equipment Property, plant and equipment is stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred. Depreciation is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements and certain leased plant and equipment, the shorter of the useful life of the asset and the term of lease as follows: ● Plant and equipment 2 - 5 years ● Furniture, fittings and equipment 3 - 15 years ● Right-of-use assets 3 years The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount. Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss. (p) Intangible assets Research and development Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense when it is incurred. Expenditure on development activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved products or services before the start of commercial production or use, is capitalized if it is probable that the product or service is technically and commercially feasible, will generate probable economic benefits, adequate resources are available to complete development and cost can be measured reliably. Other development expenditure is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense as incurred. (q) Trade and other payables These amounts represent liabilities for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method. (r) Employee benefits (i) Short-term obligations Liabilities for wages and salaries, including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet. (ii) Other long-term employee benefit obligations In some countries, the group also has liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. These obligations are therefore measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the end of the reporting period of high-quality corporate bonds with terms and currencies that match, as closely as possible, the estimated future cash outflows. Remeasurements as a result of experience adjustments and changes in actuarial assumptions are recognized in profit or loss. The obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur. (iii) Share-based payments Share-based compensation benefits are provided to employees via the Omnibus Incentive Plan (OIP). Employee options The fair value of options granted under the OIP is recognized as a share-based payment expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted: - including any market performance conditions (e.g. the company’s share price); - excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the company over a specified time period); and - including the impact of any non-vesting conditions (e.g. the requirement for employees to save or holdings shares for a specific period of time). The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the entity revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. It recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity. (s) Contributed equity Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. (t) Loss per share (i) Basic loss per share Basic loss per share is calculated by dividing: ● the loss attributable to owners of the company, excluding any costs of servicing equity other than ordinary shares ● by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year. (ii) Diluted loss per share Diluted loss per share adjusts the figures used in the determination of basic loss per share to take into account: ● the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and ● the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares. (u) Rounding of amounts The company is of a kind referred to in ASIC Legislative Instrument 2016/191, relating to the ‘rounding off’ of amounts in the financial statements. Amounts in the financial statements have been rounded off in accordance with the instrument to the nearest dollar. (v) Goods and services tax (GST) Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated balance sheet. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the taxation authority, are presented as operating cash flows. (w) Parent entity financial information The financial information for the parent entity, Immuron Limited, disclosed in Note 21 has been prepared on the same basis as the consolidated financial statements, except that accounted for at cost in the financial statements of Immuron Limited.

Critical Accounting Estimates a

Critical Accounting Estimates and Judgments	12 Months Ended
	Jun. 30, 2022
Disclosure Of Accounting Judgements And Estimates Text Block Abstract
Critical Accounting Estimates and Judgments	Note 2. Critical Accounting Estimates and Judgments Management evaluates estimates and judgments incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both internally and externally. Share-based payments The value attributed to share options and remunerations shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options to shares and the value of volatility of the price of the underlying shares. Fair value of options granted The assessed fair value of options at grant date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions. Impairment of inventories The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventory, and in particular, the shelf life of inventories that affects obsolescence. Expected shelf-life is reassessed on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company. A comprehensive stability study was completed in August 2020 and the reported findings support a shelf life of at least 130 months for the colostrum drug substance. During year ended 30 June 2022, there was no finished goods impairment (2021: $328,833) and no raw materials impairment of inventories (2021: $430,932) recognized as a provision for inventory obsolescence in the consolidated statement of profit or loss and other comprehensive income. Sales returns Returns and refunds are provided where this is outlined in a customer agreement. The group does not have a formal policy in place relating to stock returns. In cases where we have a contract in place with a distributor, and that contract includes a stock return policy, we will adhere to the policy listed in the contract. For all other distributors, stock returns are negotiated on a case-by-case basis. The exception to this is where stock is short dated to within 3 months. In this case we will offer replacement stock or a refund. The sales return provision has been assessed by management based on external reports on stock held by distributors. The timing and amount of the obligation are uncertain but are expected to be settled in the next year. The stock included in the provision is expiring within 6 months of the reporting period-end and not expected to be salable after returns. Inventory split During the year ended 30 June 2022, management performed an assessment of its raw materials and utilization within 12 months from reporting date. Management determined $137,206 of raw materials relating to Colostrum will be consumed within 12 months from reporting date (2021: Nil R&D tax incentive The Group’s research and development activities are eligible under an Australian Government tax incentive for eligible expenditure from July 1, 2011. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. For the year ended June 30, 2022 the Group has recorded other income of $257,500 (2021: $356,209) to recognise income over the year necessary to match the R&D tax incentive on a systematic basis with the costs that they are intended to compensate. Fair value measurement hierarchy The preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgments, estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgments, estimates, and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgments and estimates will seldom equal the related actual results. The judgments, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed within the relevant sections where applicable. The fair value of the convertible notes classified as Level 3 were determined by the use of valuation model. These include discounted cash flow analysis and the use of observable inputs that required significant adjustments based on unobservable inputs.

Revenue and other income

Revenue and other income	12 Months Ended
	Jun. 30, 2022
Disclosure Of Revenue Text Block Abstract
Revenue and other income	Note 3. Revenue and other income 30 June 30 June 30 June A$ A$ A$ Revenue Revenue from Operating Activities Revenue from contracts with customers 765,193 145,776 2,518,566 Total Revenue from Operating Activities 765,193 145,776 2,518,566 Other Income Australian R&D tax incentive refund 257,500 356,209 308,225 COVID-19 government assistance - 161,600 154,904 HJF R&D grant 306,595 74,821 - MTEC R&D grant 369,045 - - Other income 24,585 24,480 10,545 Total Other Income 957,725 617,110 473,674 Other Gains/(Losses) – Net Net foreign exchange gains/(losses) 247,558 (582,528 ) 11,335 Net impairment losses - (759,765 ) - (i) Fair value of R&D tax incentive refund The group’s research and development (R&D) activities are eligible under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognized when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured. For the year ended 30 June 2022, the group has included an item in other income of $257,500 (2021: $356,209) to recognize income over the year necessary to match the R&D tax incentive on a systematic basis with the costs that they are intended to compensate. (ii) COVID-19 government assistance The group’s other grant income is recognized when compliance with the conditions attached to the grant have been determined and the group has ascertained the grant will be received. No further COVID-19 government assistance was recognized in other income for current financial year (2021: $161,600). (iii) R&D grants from HJF and MTEC The group’s other grant income is recognized when compliance with the conditions attached to the grant have been determined and the group has ascertained the grant will be received and the amount can be reliably measured. For the year ended 30 June 2022, the group has recognized $306,595 (2021: $74,821) R&D grant from the Henry M Jackson Foundation (“HJF”) and $369,045 (2021: Nil) R&D grant from Medical Technology Enterprise Consortium (“MTEC”). This is to recognize income over the year necessary to match the grants on a systematic basis with the costs that they are intended to compensate. (iv) Net impairment losses Net impairment losses result from provision for impairment of inventories. During year ended 30 June 2022, there was no finished goods impairment (2021: $328,833) and no raw materials impairment of inventories (2021: $430,932) recognized as a provision for inventory obsolescence in the consolidated statement of profit or loss and other comprehensive income.

Expenses

Expenses	12 Months Ended
	Jun. 30, 2022
Disclosure Of Expenses By Nature Text Block Abstract
Expenses	Note 4. Expenses 30 June 30 June 30 June General and administrative expenses Accounting and audit 499,331 547,055 389,798 Bad debts - 5,472 26,983 Consulting 226,710 126,215 181,474 Depreciation 42,606 43,662 44,056 Employee benefits 1,212,721 1,775,809 1,531,037 Expected credit losses 8,809 (30,055 ) (3,991 ) Insurance 401,121 341,202 469,844 Investor relations 38,567 38,568 197,839 Legal 520,698 205,722 184,382 Listing and share registry 164,949 292,113 212,236 Occupancy - - 51,973 Superannuation 62,647 41,964 48,877 Travel and entertainment 9,459 1,398 91,347 Share-based payment expenses 94,890 2,116,013 (533,912 ) Other 241,880 589,554 278,135 3,524,388 6,094,692 3,170,078 Research and development expenses Consulting 230,684 1,006,086 262,720 Project research and development 427,031 360,968 915,965 657,715 1,367,054 1,178,685 Selling and marketing expenses Selling 57,854 25,858 340,046 Marketing 113,472 90,652 295,261 Distribution costs 245,211 171,174 236,244 416,537 287,684 871,551

Income Tax Expense

Income Tax Expense	12 Months Ended
	Jun. 30, 2022
Disclosure Of Income Tax Text Block Abstract
Income Tax Expense	Note 5. Income Tax Expense 30 June 30 June Unused tax losses for which no deferred tax asset has been recognized 48,058,129 44,178,579 Potential tax benefit 25% (2021: 26%) 12,014,532 11,486,431 The group operates in different tax jurisdictions and continues to meet its statutory requirements in these jurisdictions. The tax losses in each jurisdiction are subject to testing to make sure they meet all relevant statutory tests for them to be offset against future income. The group is currently undergoing an analysis for utilization of the carried forward losses. Numerical reconciliation of income tax expense to prima facie tax payable 30 June 30 June Loss from continuing operations before income tax expense (2,854,254 ) (8,384,465 ) Tax at the Australian tax rate of 25% (2021: 26%) (713,564 ) (2,179,961 ) Tax effect of amounts which are not deductible (taxable) in calculating taxable income: R&D tax incentive (64,375 ) (92,614 ) Accounting expenditure subject to R&D tax incentive 147,989 212,907 Share-based payments 23,723 550,163 Net impact of other amounts not deductible (taxable) (363,661 ) 428,003 Subtotal (969,888 ) (1,081,502 ) Tax losses and other timing differences for which no deferred tax asset is recognized 969,888 1,081,502 Income tax expense - -

Key Management Personnel Compen

Key Management Personnel Compensation	12 Months Ended
	Jun. 30, 2022
Disclosure Of Information About Key Management Personnel Text Block Abstract
Key Management Personnel Compensation	Note 6. Key Management Personnel Compensation This note details the nature and amount of remuneration for each Director of Immuron Limited, and for the Key Management Personnel. The Directors of Immuron Limited during the year ended June 30, 2022 were: The following persons held office as Directors of Immuron Limited during the financial year: Dr. Roger Aston, Independent Non-Executive Chairman Mr. Peter Anastasiou, Executive Vice Chairman (resigned on 24 September 2021) Mr. Daniel Pollock, Independent Non-Executive Director Mr. Stephen Anastasiou, Independent Non-Executive Director Prof. Ravi Savarirayan, Independent Non-Executive Director Mr. Paul Brennan, Independent Non-Executive Director (appointed on 16 March 2022) The following persons held office as Key Management Personnel of Immuron Limited during the financial year ended June 30, 2022: Dr. Jerry Kanellos, Chief Operating Officer (resigned as Chief Executive Officer on 27 June 2022) Mr. Steven Lydeamore, Chief Executive Officer (appointed on 27 June 2022) The aggregate compensation made to Directors and Other Key Management Personnel of the Company is set out below: 30 June 30 June 30 June A$ A$ A$ Key Management Personnel Compensation Short-term employee benefits 636,673 450,002 867,054 Other short-term benefits, including consulting services by KMP and their related entities — 1,603,747 — Post-employment benefits 44,489 27,869 29,213 Long-term benefits 15,168 8,220 3,610 Share-based payment expenses to KMP and their related entities 94,890 2,116,012 73,088 Total Key Management Personnel Compensation 791,220 4,205,850 972,965

Loss per Share

Loss per Share	12 Months Ended
	Jun. 30, 2022
Disclosure Of Earnings Per Share Text Block Abstract
Loss per Share	Note 7. Loss per Share 30 June 30 June 30 June A$ A$ A$ Basic/Diluted loss per share (in cents) 1.25 3.79 1.66 a) Net loss used in the calculation of basic and diluted loss per share 2,854,254 8,384,465 2,927,206 b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share 227,579,684 221,062,229 176,393,354 The Company is currently in a loss making position and thus the impact of potential issuance of shares is concluded as anti-dilutive which includes the Company’s options and warrants and convertible notes payable. Treasury shares are excluded from the calculation of weighted average number of ordinary shares.

Financial assets and financial

Financial assets and financial liabilities	12 Months Ended
	Jun. 30, 2022
Disclosure Of Redesignated Financial Assets And Liabilities Text Block Abstract
Financial assets and financial liabilities	Note 8. Financial assets and financial liabilities (a) Cash and cash equivalents 30 June 30 June A$ A$ Cash at Bank and in hand: Cash at bank and in hand 22,110,278 25,047,281 Total 22,110,278 25,047,281 (b) Trade and other receivables 30 June 30 June A$ A$ Current Trade receivables 1 217,154 28,553 Loss allowance (8,809 ) - Accrued income – Australian R&D tax incentive refund 2 257,500 306,154 Other income receivables – R&D grants 3 197,051 - Total 662,896 334,707 1 All trade receivables are non-interest bearing. 2 Receivables from the Australian Tax Office in relation to R&D tax incentive refund for the year. 3 As at 30 June 2022, the group has other income receivables of $100,328 R&D grant from the Henry M Jackson Foundation (“HJF”) and $96,723 R&D grant from Medical Technology Enterprise Consortium (“MTEC”). (c) Other current assets 30 June 30 June A$ A$ Prepayment 572,400 78,258 Total 572,400 78,258 (d) Trade and other payables 30 June 30 June Current Trade payables 720,867 106,893 Accrued expenses 411,913 625,980 Other payables 28,113 25,621 Total 1,160,893 758,494

Non-financial assets and liabil

Non-financial assets and liabilities	12 Months Ended
	Jun. 30, 2022
Nonfinancial Assets And Liabilities Abstract
Non-financial assets and liabilities	Note 9. Non-financial assets and liabilities (a) Property, plant and equipment Non-current Plant and equipment Furniture, fittings and equipment Right-of-use assets Total At 1 July 2020 Cost or fair value 348,178 35,042 115,977 499,197 Accumulated depreciation (336,051 ) (34,491 ) (57,882 ) (428,424 ) Net book amount 12,127 551 58,095 70,773 Year ended 30 June 2021 Opening net book amount 12,127 551 58,095 70,773 Additions 6,630 - - 6,630 Depreciation charge (4,761 ) (277 ) (38,624 ) (43,662 ) Closing net book amount 13,996 274 19,471 33,741 Non-current Plant and equipment Furniture, fittings and equipment Right-of-use assets Total At 30 June 2021 Cost or fair value 354,808 35,042 115,977 505,827 Accumulated depreciation (340,812 ) (34,768 ) (96,506 ) (472,086 ) Net book amount 13,996 274 19,471 33,741 Plant and equipment Furniture, fittings and equipment Right-of-use assets Total Year ended 30 June 2022 Opening net book amount 13,996 274 19,471 33,741 Additions 10,048 - - 10,048 Lease modification - - 209,560 209,560 Depreciation charge (4,531 ) (137 ) (21,945 ) (26,613 ) Closing net book amount 19,513 137 207,086 226,736 At 30 June 2022 Cost or fair value 364,856 35,042 229,031 628,929 Accumulated depreciation and impairment (345,343 ) (34,905 ) (21,945 ) (402,193 ) Net book amount 19,513 137 207,086 226,736 (b) Inventories 30 June 30 June Current Non- Total Current Non- Total Raw materials and stores (Colostrum) 137,206 956,936 1,094,142 - 1,266,587 1,266,587 Work in progress 124,412 - 124,412 - - - Finished goods (Travelan and Protectyn) 64,923 - 64,923 292,532 - 292,532 Other inventories 37 - 37 - - - 326,578 956,936 1,283,514 292,532 1,266,587 1,559,119 (i) Impairment of inventories The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventory, and in particular, the shelf life of inventories that affects obsolescence. Expected shelf-life is reassessed on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company. A comprehensive stability study was completed in August 2020 and the reported findings support a shelf life of at least 130 months for the colostrum drug substance. During year ended 30 June 2022, there was no finished goods impairment (31 December 2021: $218,506, 30 June 2021: $328,833). All short-dated finished goods as at 30 June 2022 have been written off, resulting in no provision for finished goods impairment as at 30 June 2022. In addition, there was no raw materials impairment of inventories (31 December 2021: nil (c) Employee benefit obligations 2022 2021 Current Non- Total Current Non- Total Leave obligations (i) 211,776 36 211,812 129,837 36,196 166,033 (i) Leave obligations The current portion of this liability includes all of the accrued annual leave, the unconditional entitlements to long service leave where employees have completed the required period of service and also for those employees that are entitled to pro-rata payments in certain circumstances. Total leave provision of A$211,776 (2021: A$129,837) is presented as current, since the group does not have an unconditional right to defer settlement for any of these obligations. However, based on past experience, the group does not expect all employees to take the full amount of accrued leave or require payment within the next 12 months. (d) Leases (i) Amounts recognized in the balance sheet The balance sheet shows the following amounts relating to leases: 30 June 30 June Right-of-use assets 1 Properties 207,086 19,471 207,086 19,471 Lease liabilities 2 Current 34,376 20,498 Non-current 175,411 - 209,787 20,498 1. Included in the line item ‘property, plant and equipment’ in the consolidated balance sheet. 2. Included in the line items ‘other current liabilities’ and ‘other non-current liabilities’ in the consolidated balance sheet. (ii) Amounts recognized in the statement of profit or loss The statement of profit or loss shows the following amounts relating to leases: 2022 2021 Depreciation charge of right-of-use assets Properties 37,937 38,624 37,937 38,624 Interest expense (included in finance cost) 6,100 1,152 Expense relating to short-term leases (included in other expenses) - Expense relating to leases of low-value assets that are not short-term leases (included in other expenses) - Expense relating to variable lease payments not included in lease liabilities (included in other expenses) - Cash paid for principal payments 36,264 40,607 The total finance cash outflow for leases in 2022 was A$6,100. The total finance cash outflow for leases in 2021 was A$1,152. (iii) The group’s leasing activities and how these are accounted for In November 2021, the group entered into a three-year commercial lease modification for office facilities in Blackburn North. This lease modification is effective from 1 January 2022 and includes an extension option for a further 3 years by written request to the landlord before 31 December 2024. There is no variability and no covenants included in the lease.

Controlled Entities

Controlled Entities	12 Months Ended
	Jun. 30, 2022
Controlled Entities Abstract
Controlled Entities	Note 10. Controlled Entities The Company’s subsidiaries at 30 June 2022 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the Company, and the proportion of ownership interests held equals the voting rights held by the Company. The country of incorporation or registration is also their principal place of business. Percentage of Country of 30 June 30 June Parent Entity: Immuron Limited Australia — — Subsidiaries of Immuron Limited: Immuron Inc. USA 100 % 100 % Anadis EPS Pty Ltd Australia 100 % 100 % IMC Canada Ltd. Canada 100 % 100 %

Provision for Sales Returns

Provision for Sales Returns	12 Months Ended
	Jun. 30, 2022
Description Of Accounting Policy For Provisions Text Block Abstract
Provision for Sales Returns	Note 11. Provision for Sales Returns 2022 2021 Sales return provision due to the ongoing COVID-19 pandemic Carrying amount at the start of the year 213,024 - Sales return provision recognized 71,025 213,024 Sales return made during the year (188,118 ) - Carrying amount at the end of the year 95,931 213,024 The sales return provision has been assessed by management based on external reports on stock held by distributors. The timing and amount of the obligation are uncertain but are expected to be settled in the next year. The stock included in the provision is expiring within 6 months of the reporting period-end and not expected to be saleable after returns.

Contingent Liabilities and Comm

Contingent Liabilities and Commitments	12 Months Ended
	Jun. 30, 2022
Disclosure Of Commitments And Contingent Liabilities Text Block Abstract
Contingent liabilities and Commitments	Note 12. Contingent liabilities and Commitments The group had no contingent liabilities or commitments at June 30, 2022 (2021: Nil

Share Capital

Share Capital	12 Months Ended
	Jun. 30, 2022
Disclosure Of Classes Of Share Capital Text Block Abstract
Share capital	Note 13. Share capital 2022 2021 2020 2022 2021 2020 Ordinary shares Fully paid 227,798,346 227,246,596 178,279,566 88,436,263 88,361,303 62,426,991 227,798,346 227,246,596 178,279,566 88,436,263 88,361,303 62,426,991 (i) Movements in ordinary shares: Details Number of shares Total Balance at 30 June 2019 163,215,706 60,289,875 Issue at US$0.10 pursuant to ADS public offering (2019-07-19) 13,565,200 1,926,186 Issue at A$0.16 in lieu of payment for services (2019-11-12) 1 437,500 100,978 Exercise of NASDAQ Warrants (2020-06-23) 86,240 72 Exercise of representative warrants (2020-06-15, 2020-06-22) 974,920 540,062 Transaction costs arising on representative warrants issued — (55,454 ) Less: Transaction costs arising on share issues — (374,728 ) Balance at 30 June 2020 178,279,566 62,426,991 Exercise of representative warrants (2020-07-02) 5,720 - Issue at US$0.47 pursuant to ADS public offering (2020-07-24) 42,666,720 28,165,836 Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24) 100,000 50,000 Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27) 3,008,000 1,051,626 Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29) 40,000 13,959 Transfer from reserves on exercise of ESOP unlisted options (2020-07-24) - 15,700 Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29) - 1,012 Issue at A$0.08 in lieu of cash for services rendered (2020-11-13) 2,737,500 219,000 Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09) 409,090 197,010 Less: Transaction costs arising on share issues - (3,779,831 ) Balance at 30 June 2021 227,246,596 88,361,303 Issue at $0.12 under ESOP Plan (2021-11-05) 333,000 39,960 Issue at $0.16 in lieu of payment for services (2021-12-17) 218,750 35,000 Less: Transaction costs arising on share issues - - Balance at 30 June 2022 227,798,346 88,436,263 Notes 1. Mr Peter Anastasiou (resigned 24 September 2021) and Mr Stephen Anastasiou are directors and majority shareholders of Grandlodge Capital Pty Ltd (Grandlodge). As per an agreement which commenced on 1 June 2013 and expired on 30 June 2020, Immuron Limited contracted Grandlodge on normal commercial terms and conditions to provide warehousing, distribution and invoicing services for Immuron Limited’s products for A$70,000 per annum. These fees would be payable in new fully paid ordinary shares in Immuron Limited at a set price of A$0.16 per share, representing Immuron Limited’s shares price at the commencement of the agreement. The above amount is the fair value of the equity instrument. (ii) Ordinary shares Ordinary shares entitle the holder to participate in dividends, and to share in the proceeds of winding up the company in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote. Ordinary shares have no par value and the Company does not have a limited amount of authorized capital. (iii) Options Information relating to options, including details of options issued, exercised and lapsed during the financial year and options outstanding at the end of the reporting period, is set out in notes 14 and 17.

Other Reserves

Other Reserves	12 Months Ended
	Jun. 30, 2022
Disclosure Of Reserves Within Equity Text Block Abstract
Other reserves	Note 14. Other reserves The following table shows a breakdown of the consolidated statement of financial position line item ‘other reserves’ and the movements in these reserves during the year. A description of the nature and purpose of each reserve is provided below the table. Notes Share-based Foreign Total other At 1 July 2019 4,281,790 18,529 4,300,319 Currency translation differences - 102,938 102,938 Other comprehensive income - 102,938 102,938 Transactions with owners in their capacity as owners Share-based payment expenses 16(iv) 73,088 - 73,088 Options and warrants issued/expensed (484,680 ) - (484,680 ) Options and warrants lapsed/expired (2,251,320 ) - (2,251,320 ) Remeasurement of options issued in prior period 16(iii) (607,000 ) - (607,000 ) At 30 June 2020 1,011,878 121,467 1,133,345 Notes Share-based Foreign Total other At 1 July 2020 1,011,878 121,467 1,133,345 Currency translation differences - (14,953 ) (14,953 ) Other comprehensive income - (14,953 ) (14,953 ) Transactions with owners in their capacity as owners Transfer to share capital 16(iv) (73,088 ) - (73,088 ) Options and warrants issued/expensed 16(ii) 3,003,060 - 3,003,060 Options and warrants exercised 16(ii) (213,722 ) - (213,722 ) Options and warrants forfeited (368,000 ) - (368,000 ) At 30 June 2021 3,360,128 106,514 3,466,642 Notes Share-based Foreign Total other At 1 July 2021 3,360,128 106,514 3,466,642 Currency translation differences - 6,708 6,708 Other comprehensive income - 6,708 6,708 Transactions with owners in their capacity as owners Options and warrants issued/expensed 16(ii) 54,930 - 54,930 Options and warrants lapsed/expired (361,861 ) - (361,861 ) At 30 June 2022 3,053,197 113,222 3,166,419 (i) Nature and purpose of other reserves Share-based payments The share-based payment reserve records items recognized as expenses on valuation of share options and warrants issued to key management personnel, other employees and eligible contractors. Foreign currency translation Exchange differences arising on translation of foreign controlled entities are recognized in other comprehensive income as described in note 1(d) and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of. (ii) Movements in options and warrants: Details Notes Number of options Total Balance at 30 June 2019 79,463,744 4,281,790 Remeasurement of options issued in prior period (2019-11-06) 16(iii) - (607,000 ) Issue of representative warrants (2019-07-16) 542,600 55,454 Lapse of unexercised options at $0.50 (2019-11-27) (7,625,532 ) (2,086,920 ) Lapse of unexercised options at $0.55 (2019-11-30) (25,289,894 ) - Lapse of unexercised options at $0.50 (2020-06-30) (2,000,000 ) (164,400 ) Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23) (218,800 ) (72 ) Exercise of representative warrants (2020-06-15, 2020-06-22) (2,065,000 ) (540,062 ) Share-based payments expenses - 73,088 Balance at 30 June 2020 42,807,118 1,011,878 Exercise of representative warrants (2020-07-2) (9,640 ) - Exercise of ESOP unlisted options at $0.50 (2020-07-24) (100,000 ) (15,700 ) Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29) (3,048,000 ) (1,012 ) Lapse of unexercised options (2020-09-25) (5,000,000 ) (368,000 ) Issue of representative warrants at US$23.44 per 40 options (2020-07-24) 2,560,000 1,032,960 Issue of ESOP unlisted options at $0.12 (2020-10-29) 9,000,000 1,970,100 Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09) (900,000 ) (197,010 ) Reclassify share-based payments expenses from reserves to share capital 16(iv) - (73,088 ) Balance at 30 June 2021 45,309,478 3,360,128 Lapse of unexercised options at $0.50 (2021-07-01) (1,200,000 ) (188,400 ) Issue of ESOP unlisted options at $0.25 (2021-11-05) 500,000 18,624 Lapse of unexercised options at $1.94 (2021-11-30) (14,493 ) (28,813 ) Lapse of unexercised options at $1.94 (2022-06-14) (24,721,108 ) (144,648 ) ESOP unlisted options granted at $0.12 (2022-06-27) - 36,306 Balance at 30 June 2022 19,873,877 3,053,197 Given the shareholders’ approval at the AGM held on 29 October 2020, a total of 9,000,000 ESOP Options were issued to directors on 13 November 2020. On 05 November 2021, the Company issued Dr. Jerry Kanellos, Chief Operating Officer of Immuron Limited, 500,000 unlisted options exercisable at $0.25 on or before 26 October 2025. On 27 June 2022, the Company granted Mr. Steven Lydeamore, Chief Executive Officer of Immuron Limited, 1,430,000 unlisted options exercisable at $0.12 on or before 27 June 2026. The options were subsequently issued after the reporting period, on 1 July 2022. (iii) Remeasurement of options issued in prior period Options granted to a former managing director on 11 February 2019 and valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a remeasurement of $607,000 in the 30 June 2020 financials. (iv) Reclassification of share-based payment expenses Due to the ongoing crisis of COVID-19, the groups directors decided to forgo cash payments of their director fees from 1 April 2020 to 31 December 2020 and instead receive shares of that value. In prior year, no shares were issued to directors, however the expense of the shares owed to them was A$73,088. As at 30 June 2021, shares have been issued to directors given the shareholders’ approval at the AGM held on 29 October 2020.

Segment Reporting

Segment Reporting	12 Months Ended
	Jun. 30, 2022
Disclosure Of Entitys Operating Segments Text Block Abstract
Segment Reporting	Note 15. Segment Reporting Description of segments and principal activities The group has identified its operating segments based on the internal reports that are reviewed and used by the executive management team in assessing performance and determining the allocation of resources. Management considers the business from both a product and a geographic perspective and has identified two reportable segments: Research and development (R&D): income and expenses directly attributable to the group’s R&D projects performed in Australia, Israel and United States. Hyperimmune products: income and expenses directly attributable to Travelan and Protectyn activities which occur in Australia, the United States, Canada and the rest of the world. Financial breakdown The segment information for the reportable segments for the year ended June 30, 2022 is as follows: Research Hyperimmune products Other Total 2022 A$ A$ A$ A$ Hyperimmune products revenue - 765,193 - 765,193 Cost of sales of goods - (241,691 ) - (241,691 ) Gross profit - 523,502 - 523,502 Other income 933,140 24,585 - 957,725 Net foreign exchange gains/(losses) - - 247,558 247,558 General and administrative expenses - (164,087 ) (3,360,301 ) (3,524,388 ) Research and development expenses (657,715 ) - - (657,715 ) Selling and marketing expenses - (416,537 ) - (416,537 ) Operating profit/(loss) 275,425 (32,537 ) (3,112,743 ) (2,869,855 ) Finance income - - 21,785 21,785 Finance costs - - (6,184 ) (6,184 ) Income tax expense - - - - Profit/(loss) for the year 275,425 (32,537 ) (3,097,142 ) (2,854,254 ) Assets Segment assets 257,500 1,688,910 22,909,414 24,855,824 Total assets 257,500 1,688,910 22,909,414 24,855,824 Liabilities Segment liabilities 7,053 150,151 1,521,219 1,678,423 Total liabilities 7,053 150,151 1,521,219 1,678,423 The segment information for the reportable segments for the year ended June 30, 2021 is as follows: Research Hyperimmune Other Total 2021 A$ A$ A$ A$ Hyperimmune products revenue - 145,776 - 145,776 Cost of sales of goods - (51,071 ) - (51,071 ) Gross profit - 94,705 - 94,705 Other income 431,030 24,480 161,600 617,110 Net foreign exchange gains/(losses) - - (582,528 ) (582,528 ) Net impairment losses - (759,765 ) - (759,765 ) General and administrative expenses - - (6,094,692 ) (6,094,692 ) Research and development expenses (1,367,054 ) - - (1,367,054 ) Selling and marketing expenses - (287,684 ) - (287,684 ) Operating profit/(loss) (936,024 ) (928,264 ) (6,515,620 ) (8,379,908 ) Finance income - - 9,204 9,204 Finance costs - - (13,761 ) (13,761 ) Income tax expense - - - - Profit/(loss) for the year (936,024 ) (928,264 ) (6,520,177 ) (8,384,465 ) Assets Segment assets 306,154 1,587,672 25,159,280 27,053,106 Total assets 306,154 1,587,672 25,159,280 27,053,106 Liabilities Segment liabilities 243,565 284,657 629,827 1,158,049 Total liabilities 243,565 284,657 629,827 1,158,049 The segment information for the reportable segments for the year ended June 30, 2020 is as follows: Research Hyperimmune Other Total 2020 A$ A$ A$ A$ Hyperimmune products revenue - 2,518,566 - 2,518,566 Cost of sales of goods - (688,836 ) - (688,836 ) Gross profit - 1,829,730 - 1,829,730 Other income 308,225 10,545 154,904 473,674 Net foreign exchange gains/(losses) - - 11,335 11,335 General and administrative expenses - - (3,170,078 ) (3,170,078 ) Research and development expenses (1,178,685 ) - - (1,178,685 ) Selling and marketing expenses - (871,551 ) - (871,551 ) Operating profit/(loss) (870,460 ) 968,724 (3,003,839 ) (2,905,575 ) Finance income - - - - Finance costs - - (21,631 ) (21,631 ) Income tax expense - - - - Profit/(loss) for the year (870,460 ) 968,724 (3,025,470 ) (2,927,206 ) Assets Segment assets 308,225 2,539,503 3,354,435 6,202,163 Total assets 308,225 2,539,503 3,354,435 6,202,163 Liabilities Segment liabilities 101,092 30,377 426,781 558,250 Total liabilities 101,092 30,377 426,781 558,250 Information on geographical regions: The group derives revenue from the transfer of hyperimmune products at a point in time in the following major product lines and geographical regions: Travelan Protectyn Australia United States Canada Australia Total 2022 A$ A$ A$ A$ A$ Hyperimmune products revenue 143,378 501,228 63,172 57,415 765,193 Revenue from external customers 143,378 501,228 63,172 57,415 765,193 Travelan Protectyn Australia United States Canada Australia Total 2021 A$ A$ A$ A$ A$ Hyperimmune products revenue 1 (10,308 ) 4,264 101,639 50,181 145,776 Revenue from external customers (10,308 ) 4,264 101,639 50,181 145,776 1. Returns are provided where outlined in a customer’s agreement. Travelan Protectyn Australia United States Canada Australia Total 2020 A$ A$ A$ A$ A$ Hyperimmune products revenue 1,240,393 926,325 301,915 49,933 2,518,566 Revenue from external customers 1,240,393 926,325 301,915 49,933 2,518,566 Information on major customers: During the years ended June 30, 2022, 2021 and 2020, the Company had the following major customers in the hyperimmune product segment with revenues amounting to 10 percent or more of total group revenues: 2022 A$ 2021 A$ 2020 A$ Customer A 263,137 - 327,559 Customer B 253,803 23,214 462,490 Customer C 99,792 - 438,065 Customer D - - 442,916 Customer E - - 227,952 Customer F - 41,040 - Customer G - 27,563 - Customer H - 25,319 - Customer I - 22,886 - 616,732 140,022 1,898,982

Cash Flow Information

Cash Flow Information	12 Months Ended
	Jun. 30, 2022
Disclosure Of Cash Flow Information Explanatory Abstract
Cash Flow Information	Note 16. Cash Flow Information (a) Reconciliation of cash flow from operations with loss after income tax 30 June 30 June 30 June Net Loss for the Year (2,854,254 ) (8,384,465 ) (2,927,206 ) Adjustments for Depreciation expense 26,613 43,662 44,056 Lease modification 15,993 - - Distribution costs 35,000 - 70,000 Expected credit losses 8,809 (30,055 ) (3,991 ) Finance costs 6,184 13,761 21,631 Finance income (21,785 ) (9,204 ) - Leave provision expense 45,470 53,610 19,717 Share-based payments (income)/expenses 94,891 2,116,013 (533,912 ) Unrealized net foreign currency gains (234,794 ) 592,243 (18,883 ) Change in operating assets and liabilities: Add decrease in trade and other receivables (336,998 ) 23,037 641,236 Add (increase) / decrease in inventories 275,605 960,920 (113,635 ) Add (increase) / decrease in other operating assets (494,143 ) (45,065 ) 16,096 Add (decrease) / increase in trade and other payables 285,616 586,796 (362,437 ) (3,147,793 ) (4,078,747 ) (3,147,328 ) (b) Non-cash financing and investing activities See note 17 for details regarding issues of options to employees and for details surrounding the issue of shares to suppliers.

Share-based Payments

Share-based Payments	12 Months Ended
	Jun. 30, 2022
Disclosure Of Share Based Payment Arrangements Text Block Abstract
Share-based Payments	Note 17. Share-based Payments a) Executive share and option plan The establishment of the Omnibus Incentive Plan (OIP) was approved by shareholders at the 2021 annual general meeting. The plan is designed to provide long-term incentives for executives (including directors) to deliver long-term shareholder returns. Participation in the plan is at the board’s discretion and no individual has a contractual right to participate in the plan or to receive any guaranteed benefits. Set out below are summaries of all listed and unlisted options, including those issued under OIP: 2022 2021 2020 Average Number of Average Number of options Average Number of As at 1 July 0.31 45,309,478 0.40 42,807,118 0.46 79,463,744 Granted during the year 0.25 500,000 0.28 11,560,000 0.18 542,600 Exercised during the year - - 0.23 (4,057,640 ) 0.18 (424,840 ) Forfeited/lapsed during the year 0.27 (25,935,601 ) 0.50 (5,000,000 ) 0.52 (36,774,386 ) As at 30 June 0.37 19,873,877 0.31 45,309,478 0.40 42,807,118 Vested and exercisable at 30 June 0.37 19,538,877 0.31 45,309,478 0.40 42,807,118 Share options outstanding at the end of the year have the following expiry date and exercise prices: Exercise Share Share Share Grant date Expiry (A$ unless 30 June 30 June 30 June 2012-06-29 2021-11-30 1.944 - 14,493 14,493 2012-06-29 2022-01-17 1.876 - 29,668 29,668 2017-06-13 (warrants) 2022-06-13 USD 0.25 - 24,493,200 27,541,200 2018-03-15 2023-03-15 0.468 7,897,647 7,897,647 7,897,647 2017-06-09 (warrants) 2022-06-08 USD 0.3125 198,240 198,240 2018-03-15 2023-03-15 0.585 526,510 526,510 526,510 2019-05-23 (warrants) 2024-05-23 USD 0.125 173,600 173,600 181,600 2019-07-16 (warrants) 2024-07-16 USD 0.125 116,120 116,120 117,760 2018-07-13 2021-07-01 0.500 - 1,200,000 1,300,000 2019-11-06 2024-02-10 0.500 - - 5,000,000 2020-10-29 2024-04-14 0.12 8,100,000 8,100,000 - 2020-07-24 (warrants) 2025-07-21 USD 0.5859 2,560,000 2,560,000 - 2021-10-26 2025-10-26 0.25 500,000 - - Total 19,873,877 45,309,478 42,807,118 Weighted average remaining contractual life of options outstanding at end of period 1.54 1.58 2.28 (i) Fair value of options granted The assessed fair value of options at grant date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions. The model inputs for options granted under OIP during the year ended June 30, 2022 included: Grant date Expiry date Exercise No. of Share price Expected Dividend Risk- free Fair value 2021-10-26 2025-10-26 0.25 500,000 0.12 131.70 % 0.00 % 0.69 % 0.0886 2022-06-27 2026-06-27 0.12 1,430,000 * 0.07 128.10 % 0.00 % 3.31 % 0.0530 1,930,000 * 1,430,000 options granted to Mr. Lydeamore on 27 June 2022 and subsequently issued after the reporting period, on 1 July 2022. The model inputs for options granted under OIP during the year ended June 30, 2021 included: Grant date Expiry date Exercise price No. of Share price Expected Dividend Risk- free Fair value 2020-07-24 2025-07-21 0.83 2,560,000 0.50 127.93 % 0.00 % 0.43 % 0.4035 2020-10-29 2024-04-14 0.12 9,000,000 0.25 142.70 % 0.00 % 0.13 % 0.2189 11,560,000 The model inputs for options granted under OIP during the year ended June 30, 2020 included: Grant date Expiry date Exercise No. of Share price Expected Dividend Risk- free Fair value 2019-11-06 2024-02-10 0.50 5,000,000 * 0.15 98 0.00 % 0.88 % 0.0736 5,000,000 * Options issued to a former managing director expire within 6 months upon his resignation on 25 March 2020 without good reason or termination. The expected life of the options is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome. b) Expenses arising from share-based payment transactions Total expenses arising from share-based payment transactions recognized during the period were as follows: 2022 2021 2020 1 Options issued under OIP 54,930 1,970,100 (607,000 ) Shares issued under OIP 39,960 - - Share-based payments to KMP 2 - 145,913 73,088 94,890 2,116,013 (533,912 ) 1. Options granted to a former managing director on 11 February 2019 and valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a remeasurement of $607,000 in the 30 June 2020 financials. 2. In fiscal 2021, due to the ongoing crisis of COVID-19, the groups directors decided to forgo cash payments of their director fees and instead receive shares of that value. As at 30 June 2021, shares have been issued to directors for the director fees of $145,913 incurred during the financial year ended 30 June 2021 and $73,088 incurred during the financial year ended 30 June 2020, given the shareholders’ approval at the AGM held on 29 October 2020.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2022
Disclosure Of Related Party Text Block Abstract
Related Party Transactions	Note 18. Related Party Transactions (a) Subsidiaries Interests in subsidiaries are set out in note 10. (b) Transactions with other related parties The following transactions occurred with related parties: 2022 2021 2020 Amounts settled in cash or shares for goods and services Purchases of various goods and services from entities controlled by key management personnel (i) 154,364 110,607 142,347 Legal services by key management personnel (ii) 20,000 - - (i) Purchases from entities controlled by key management personnel The group acquired the following goods and services from entities that are controlled by members of the group’s key management personnel: ● rental of an office suite (Wattle Laboratories Pty Ltd); and Effective January 2016, we executed a Lease Agreement with Wattle Laboratories Pty Ltd, (“Wattle”), an entity part-owned and operated by our non-executive directors, Mr. Peter Anastasiou (a director resigned on 24 September 2021) and Mr. Stephen Anastasiou, whereby we lease part of their Blackburn office facilities for our operations, payable in monthly installments. The rental agreement is subject to annual rental increases, and effective January 2017, the annual rent was A$39,525. The lease is for a three-year term with an additional three-year option period. The lease may be terminated by either party upon six months’ written notice. The lease was renewed, commencing January 1, 2019 at a rental rate of A$ 41,738 per year for three years. The lease continued to be renewed, commencing January 1, 2022 at a rental rate of A$42,990 per year for another three years. This lease includes an extension option for a further 3 years by written request to the landlord before 31 December 2024. During the fiscal years ended June 30, 2020, 2021 and 2022, we paid Wattle A$41,369, A$40,607 and A$42,364 (excluding Goods and Services Tax), respectively. ● warehousing, distribution and invoicing services (Grandlodge Capital Pty Ltd or “Grandlodge”). Grandlodge Capital Pty Ltd is an entity part-owned and operated by our non-executive director Mr. Stephen Anastasiou. Mr. Peter Anastasiou (a director resigned on 24 September 2021) and Mr. David Plush are also owners of Grandlodge, and its associated entities. Commenced on June 1, 2013, Grandlodge provides warehousing, distribution and invoicing services for our products for A$70,000 per year. The terms of the agreement were to have fees payable in new fully paid ordinary shares in Immuron Limited as a set price of A$0.16 per share. The fair value of the equity instrument has been assessed and accounted for in accordance with IFRS 2 Share Based Payments in the 2020 financial statements. During the 2020 financial year, the fees of A$100,978 equivalent were repaid by issuance of 437,500 ordinary shares based on their fair value. During the 2019 financial year, the fees of A$93,678 equivalent were repaid by issuance of 437,500 ordinary shares based on based on their fair value. Grandlodge is reimbursed in cash for all reasonable costs and expenses incurred in accordance with their scope of works under the oral agreement, unless both Grandlodge and we agree to an alternative method of payment. The oral agreement may be terminated by either party upon providing the other party with 30 days written notice of the termination of the agreement. A new annual agreement commenced on July 1, 2020 and 2021. Grandlodge was contracted on commercial terms to provide warehousing, distribution and invoicing services for Immuron’s products for A$70,000 and A$77,000 per annum, respectively. The terms of the agreement were to have fees payable in cash. Furthermore, in fiscal 2022 an additional A$35,000 was recognized and paid in shares to Grandlodge as per the shareholders' approval at the AGM held on December 15, 2021. Aggregate amounts of each of the above types of other transactions with key management personnel of Immuron Limited: 2021 2021 2020 Amounts settled in cash or shares during the period Rental of an office suite from Wattle Laboratories Pty Ltd 42,364 40,607 41,369 Services rendered by Grandlodge Capital Pty Ltd 112,000 70,000 100,978 154,364 110,607 142,347 ii) Legal services by key management personnel During the fiscal year 2022, the group engaged a non-executive director, Mr Daniel Pollock, for legal services which amounted to $20,000. (c) Outstanding balances arising from sales/purchases of goods and services The following balances are outstanding at the end of the reporting period in relation to transactions with related parties: 2022 A$ 2021 A$ 2020 A$ Current payables (purchases of goods and services) Entities controlled by key management personnel 77,000 70,000 -

Financial Risk Management Objec

Financial Risk Management Objectives and Policies	12 Months Ended
	Jun. 30, 2022
Disclosure Of Financial Risk Management Text Block Abstract
Financial Risk Management Objectives and Policies	Note 19. Financial Risk Management Objectives and Policies This note explains the Group’s exposure to financial risks and how these risks could affect the Group’s future financial performance. The Group’s risk management is predominantly controlled by the Board. The Board monitors the Group’s financial risk management policies and exposures and approves substantial financial transactions. It also reviews the effectiveness of internal controls relating to market risk, credit risk and liquidity risk. (a) Market risk Foreign exchange risk The Group undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations. Foreign exchange rate risk arises from financial assets and financial liabilities denominated in a currency that is not the group’s functional currency. Exposure to foreign currency risk may result in the fair value of future cash flows of a financial instrument fluctuating due to the movement in foreign exchange rates of currencies in which the group holds financial instruments which are other than the Australian dollar (AUD) functional currency of the group including United States dollar (USD) and Canadian dollar (CAD). This risk is measured using sensitivity analysis and cash flow forecasting. The cost of hedging at this time outweighs any benefits that may be obtained. Exposure The Group’s exposure to foreign currency risk at the end of the reporting period, expressed in Australian dollars, was as follows: 2022 2021 USD CAD ILS USD CAD ILS Cash and cash equivalents 3,138,079 29,224 - 108,688 2,742,688 108,688 - Trade receivables 279,986 - - - 23,801 - - Trade payables 73,430 803 2,240 43,466 18,556 43,466 - Total exposure 3,491,495 30,027 2,240 152,154 2,785,045 152,154 - Sensitivity As shown in the table above, the Group is primarily exposed to changes in USD/AUD exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from USD denominated financial instruments. The impact on other components of equity arises from the translation of foreign subsidiary financial statements into AUD. The Group has conducted a sensitivity analysis of its exposure to foreign currency risk. The Group is currently materially exposed to the United States dollar (USD). The sensitivity analysis is conducted on a currency-by-currency basis using the sensitivity analysis variable, which is based on the average annual movement in exchange rates over the past five years at year-end spot rates. The variable for each currency the group is materially exposed to is listed below: ● USD: 5.8% (2021: 4.9%) Impact on loss for Impact on other 2022 2021 2022 2021 USD/AUD exchange rate – change by 5.8% (2021: 4.9%) 202,507 136,467 6,567 5,219 * Holding all other variables constant Loss is more sensitive to movements in the AUD/USD exchange rates in 2022 than 2021 because of the increased amount of USD denominated cash and cash equivalents and the increased variability of the AUD/USD exchange rate. Equity is more sensitive to movements in the AUD/USD exchange rates in 2022 than 2021 because of the increased size of the foreign currency translation reserve for the subsidiary with USD functional currency. The group’s exposure to other foreign exchange movements is not material. (b) Credit risk Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss to the group. (i) Risk management Credit risk is managed through the maintenance of procedures (such as the utilization of systems for the approval, granting and renewal of credit limits, regular monitoring of exposures against such limits and monitoring the financial stability of significant customers and counterparties), ensuring to the extent possible that customers and counterparties to transactions are of sound credit worthiness. Such monitoring is used in assessing receivables for impairment. Credit terms are normally 30 days from the invoice date. Risk is also minimized through investing surplus funds in financial institutions that maintain a high credit rating. (ii) Security For some trade receivables the group may obtain security in the form of guarantees, deeds of undertaking or letters of credit which can be called upon if the counterparty is in default under the terms of the agreement. (iii) Impairment of financial assets The group has one type of financial asset subject to the expected credit loss model: ● trade receivables for sales of inventory While cash and cash equivalents are also subject to the impairment requirements of IFRS 9, the identified impairment loss was immaterial. Trade receivables The group applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. To measure the expected credit losses, trade receivables assets have been grouped based on shared credit risk characteristics and the days past due. The expected loss rates are based on the payment profiles of sales over a period of 60 months before June 30, 2022 and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. On that basis, the loss allowance as at June 30, 2022 was determined as follows for trade receivables: Days past due Current 1-30 31-60 61-90 91-120 121+ Total 30 June 2022 A$ A$ A$ A$ A$ A$ A$ Expected credit loss rate 0.00 % 0.00 % 13.08 % 24.14 % 26.84 % 0.00 % Gross carrying amount - - 7,959 664 186 - 8,809 Loss allowance - - - - - - - On that basis, the loss allowance as at June 30, 2021 was determined as follows for trade receivables: Days past due 30 June 2021 Current 1-30 31-60 61-90 91-120 121+ Total Expected credit loss rate 0.00 % 0.00 % 13.07 % 21.88 % 34.09 % 53.58 % Gross carrying amount 23,801 4,752 - - - - 28,553 Loss allowance - - - - - - - Trade receivables are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan with the group, and a failure to make contractual payments for a period of greater than 121 days past due. Impairment losses on trade receivables are presented as net impairment losses within operating profit. Subsequent recoveries of amounts previously written off are credited against the same line item. Previous accounting policy for impairment of trade receivables In the prior year, the impairment of trade receivables was assessed based on the incurred loss model. Individual receivables which were known to be uncollectible were written off by reducing the carrying amount directly. The other receivables were assessed collectively to determine whether there was objective evidence that an impairment had been incurred but not yet been identified. For these receivables the estimated impairment losses were recognized in a separate provision for impairment. The Group considered that there was evidence of impairment if any of the following indicators were present: ● significant financial difficulties of the debtor; ● probability that the debtor will enter bankruptcy or financial reorganization; and ● default or late payments (more than 121 days overdue). Receivables for which an impairment provision was recognized were written off against the provision when there was no expectation of recovering additional cash. (c) Liquidity risk Liquidity risk arises from the possibility that the group might encounter difficulty in settling its debts or otherwise meeting its obligations related to financial liabilities. The group manages this risk through the following mechanisms: ● preparing forward looking cash flow analyses in relation to its operating, investing and financing activities; ● obtaining funding from a variety of sources; ● maintaining a reputable credit profile; ● managing credit risk related to financial assets; ● investing cash and cash equivalents and deposits at call with major financial institutions; and ● comparing the maturity profile of financial liabilities with the realisation profile of financial assets. Maturities of financial liabilities The tables below analyze the group’s financial liabilities into relevant maturity groupings based on their contractual maturities. The amounts disclosed in the table are the contractual discounted cash flows. Contractual maturities Less than 6 months 6 - 12 Between Between Over Total contractual Carrying At 30 June 2022 A$ A$ A$ A$ A$ A$ A$ Trade and other payables 748,980 - - - - 748,980 748,980 Lease liabilities 34,376 - - - - 34,376 34,376 Total 748,980 - - - - 748,980 748,980 At 30 June 2021 Trade and other payables 132,514 - - - - 132,514 132,514 Lease liabilities 20,498 - - - - 20,498 20,498 Total 153,012 - - - - 153,012 153,012

Events occurring after the Repo

Events occurring after the Reporting Date	12 Months Ended
	Jun. 30, 2022
Disclosure Of Events After Reporting Period Text Block Abstract
Events occurring after the Reporting Date	Note 20. Events occurring after the Reporting Date No matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect, the operations of the group, the results of those operations or the state of affairs of the group or economic entity in subsequent financial years.

Parent Entity Financial Informa

Parent Entity Financial Information	12 Months Ended
	Jun. 30, 2022
Disclosure Of Parent Entity Financial Information Abstract
Parent entity financial information	Note 21. Parent entity financial information The individual financial statements for the parent entity show the following aggregate amounts: 2022 2021 Balance sheet Current assets 23,685,902 25,698,082 Non-current assets 1,181,517 1,300,467 Total assets 24,867,419 26,998,549 Current liabilities 1,498,834 1,118,020 Non-current liabilities 175,447 36,196 Total liabilities 1,674,281 1,154,216 (46,386,276 ) (51,688,666 ) Shareholders' equity Share capital 88,436,263 88,361,303 Reserves Share-based payments 3,053,197 3,360,128 Accumulated losses (68,296,322 ) (65,877,098 ) 23,193,138 25,844,333 Loss for the year 2,781,085 8,271,111 Total comprehensive loss 2,781,085 8,271,111 (b) Guarantees entered into by the parent entity The parent entity has not entered into any guarantees in relation to debts of its subsidiaries in the year ended 30 June 2022 (2021: nil (c) Contingent liabilities of the parent entity The parent entity did not have any contingent liabilities as at 30 June 2022 or 30 June 2021. (d) Contractual commitments for the acquisition of property, plant or equipment The parent entity has not entered into any contractual commitments for the acquisition of property, plant or equipment in the year ended 30 June 2022 (2021: nil (e) Determining the parent entity financial information The financial information for the parent entity has been prepared on the same basis as the consolidated financial statements, except as set out below. (i) Investments in subsidiaries Investments in subsidiaries are accounted for at cost in the financial statements of Immuron Limited. (ii) Intercompany loan Total comprehensive loss of the parent entity includes the fully impaired intercompany loan.

Auditors' Remuneration

Auditors' Remuneration	12 Months Ended
	Jun. 30, 2022
Disclosure Of Auditors Remuneration Text Block Abstract
Auditors' Remuneration	Note 22. Auditors’ Remuneration The following table sets forth, for each of the years indicated, the fees billed by Grant Thornton Audit Pty Ltd. Year Ended June 30, 2022 2021 Audit and review of financial statements (1) 173,631 179,742 173,631 179,742 (1) Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant can reasonably provide.

Company Details

Company Details	12 Months Ended
	Jun. 30, 2022
Disclosure Of Company Details Explanatory Abstract
Company Details	Note 23. Company Details The registered office of the Company is: Level 3, 62 Lygon Street, Carlton, Victoria, Australia 3053. The principal place of business of the Company is: Unit 10, 25-37 Chapman Street, Blackburn, Victoria, Australia 3130. Australian Disclosure Requirements All press releases, financial reports and other information are available using the stock code IMC on the Australian Stock Exchange website: www2.asx.com.au. Australian Disclosure Requirements Directors’ Declaration In the directors’ opinion: (a) the financial statements and Notes set out on pages F-1 to F-39 are in accordance with the Corporations Act 2001, including: (i) Complying with Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements, and (ii) Giving a true and fair view of the consolidated entity’s financial position as at June 30, 2022 and of its performance for the fiscal year ended on that date, and (b) There are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable. Note 1 ‘Basis of preparation’ confirms that the financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board. The directors have been given the declarations by the chief executive officer and chief financial officer required by section 295A of the Corporations Act 2001. This declaration is made in accordance with a resolution of the directors.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of preparation	(a) Basis of preparation These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board and the Corporations Act 2001 (i) Compliance with IFRS The consolidated financial statements of the Immuron Limited group also comply with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). (ii) Historical cost convention The financial statements have been prepared on a historical cost basis. (iii) Significant estimates and judgements Going concern The group is in a position to meet future commitments in the current business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress its research and development programs for at least the next 12 months. The annual report has been prepared on a going concern basis. Accordingly, the annual report does not include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of liabilities that might be necessary should the group not continue as a going concern. COVID-19 Judgement has been exercised in considering the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the group based on known information. This consideration extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the group operates. Sales of Travelan have significantly dropped from March 2020 and as at reporting date sales has started to recover. This note provides a list of the significant accounting policies adopted in the preparation of these consolidated financial statements to the extent they have not already been disclosed in the other notes above. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial statements are for the group consisting of Immuron Limited and its subsidiaries. (iv) New standards and interpretations not yet adopted There are no standards that are not yet effective and that would be expected to have a material impact on the Company in the current or future reporting years and on foreseeable future transactions. Summary of significant accounting policies The following is a summary of the material accounting policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently applied, unless otherwise stated.
Principles of consolidation	(b) Principles of consolidation (i) Subsidiaries Subsidiaries are all entities (including structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from the date that control ceases. The acquisition method of accounting is used to account for business combinations by the group. Intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group.
Segment reporting	(c) Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. This has been identified as the executive management team consisting of the CEO and COO.
Foreign currency translation	(d) Foreign currency translation (i) Functional and presentation currency Items included in the financial statements of each of the group’s entities are measured using the currency of the primary economic environment in which the entity operates (‘the functional currency’). The consolidated financial statements are presented in Australian dollar (“A$” or “$”), which is Immuron Limited’s functional and presentation currency. (ii) Transactions and balances Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss. Foreign exchange gains and losses that relate to borrowings are presented in the consolidated statement of profit or loss and other comprehensive income, within finance costs. All other foreign exchange gains and losses are presented in the consolidated statement of profit or loss and other comprehensive income on a net basis within other gains/(losses). Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair value through other comprehensive income are recognized in other comprehensive income. (iii) Group companies The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows: ● assets and liabilities for each consolidated balance sheet presented are translated at the closing rate at the date of that consolidated balance sheet; ● income and expenses for each consolidated statement of profit or loss and consolidated statement of profit or loss and other comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and ● all resulting exchange differences are recognized in other comprehensive income. On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or loss on sale.
Revenue recognition	(e) Income and revenue recognition (i) Sale of hyperimmune products Revenue arises mainly from the sale hyperimmune products. To determine whether to recognize revenue, the group follows the process of identifying the contract with a customer, identifying the performance obligations, determining the transaction price, allocating the transaction price to the performance obligations and recognizing revenue when performance obligations are satisfied. Revenue from the sale of hyperimmune products is recognized at a point in time when or as the group transfers control of the assets to the customer upon delivery of the products. There is no significant cost to obtain the contract. However, there is variable consideration due to rebates, discounts and refunds. The variable amount of consideration is allocated entirely to the distinct good that is consistent with the amount of consideration to which the group expects to be entitled in exchange for transferring the promised goods to the customer. The group offers rebates of up to 10% to some loyal wholesalers in Australia. During the financial year 2022, to improve the relatively low sales during the previous financial year, the group initiated periodic discounts of up to 50% for Protectyn products purchased by the end customers via wholesalers. There are no warranties. Returns and refunds are provided where this is outlined in a customer agreement. The group does not have a formal policy in place relating to stock returns. In cases where we have a contract in place with a distributor, and that contract includes a stock return policy, we will adhere to the policy listed in the contract. For all other distributors, stock returns are negotiated on a case-by-case basis. The exception to this is where stock is short dated to within 3 months. In this case we will offer replacement stock or a refund. (ii) Financing components The group does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the group does not adjust any of the transaction prices for the time value of money. (ii) R&D grants from HJF and MTEC The group’s other grant income is recognized when compliance with the conditions attached to the grant have been determined and the group has ascertained the grant will be received and the amount can be reliably measured. For the year ended 30 June 2022, the group has recognized $306,595 (2021: $74,821) R&D grant from the Henry M Jackson Foundation (“HJF”) and $369,045 (2021: Nil
Government grants	(f) Government grants Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received, and the group will comply with all attached conditions. Other income amounts are recognized when it has been established that the conditions of the government grants have been met and that the expected amount can be reliably measured. Government grants are recognized in profit or loss on a systematic basis over the periods in which the Group recognizes as expenses the related costs for which the grants are intended to compensate. Accrued receivables These amounts primarily comprise receivables from the Australian Taxation Office in relation to the R&D tax incentive.
Income tax	(g) Income tax The income tax expense or credit for the period is the tax payable on the current period’s taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. Current and deferred tax is recognized in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively. As per IFRIC 23 Uncertainty over Income Tax Treatments, where it is probable, the group has determined tax balances consistently with the tax treatment used or planned to be used in its income tax filings. Where the group has determined that it is not probable that the taxation authority will accept an uncertain tax treatment, the most likely amount or the expected value has been used in determining taxable balances (depending on which method is expected to better predict the resolution of the uncertainty).
Leases	(i) Leases Leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the group. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: ● fixed payments (including in-substance fixed payments), less any lease incentives receivable ● variable lease payment that are based on an index or a rate ● amounts expected to be payable by the lessee under residual value guarantees ● the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and ● payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be determined, or the group’s incremental borrowing rate. Right-of-use assets are measured at cost comprising the following: ● the amount of the initial measurement of lease liability ● any lease payments made at or before the commencement date, less any lease incentives received ● any initial direct costs, and ● restoration costs. Payments associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT-equipment and small items of office furniture.
Impairment of assets	(j) Impairment of assets An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.
Cash and cash equivalents	(k) Cash and cash equivalents For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities in the consolidated balance sheet.
Trade receivables	(l) Trade receivables Trade receivables are recognized initially at fair value and subsequently measured at amortised cost using the effective interest method, less loss allowance. The group applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. To measure the expected credit losses, trade receivables assets have been grouped based on shared credit risk characteristics and the days past due. The expected loss rates are based on the payment profiles of sales over a period of 60 months before June 30, 2022 and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. (i) Classification as trade receivables Trade receivables are amounts due from customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within 30 days and therefore are all classified as current. Trade receivables are recognized initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognized at fair value. The group holds the trade receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method. Details about the group’s impairment policies and the calculation of the loss allowance are provided below. (iii) Fair value of trade and other receivables Due to the short-term nature of the current receivables, their carrying amount is considered to be the same as their fair value. (iv) Impairment for financial instruments The Group’s risk management is predominantly controlled by the Board. The Board monitors the Group’s financial risk management policies and exposures and approves substantial financial transactions. It also reviews the effectiveness of internal controls relating to market risk, credit risk and liquidity risk. The Board is responsible for overseeing the establishment and implementation of the risk management system, and reviews and assesses the effectiveness of the Company’s implementation of that system on a regular basis. The Board and Senior Management identify the general areas of risk and their impact on the activities of the Company, with Management performing a regular review of: Ø the major risks that occur within the business; the degree of risk involved; Ø the current approach to managing the risk; and Ø if appropriate, determine: ○ any inadequacies of the current approach; and ○ possible new approaches that more efficiently and effectively address the risk. Management report risks identified to the Board through the monthly Operations Report. The Company seeks to ensure that its exposure to undue risk which is likely to impact its financial performance, continued growth and survival is minimized in a cost effective manner.
Inventories	(m) Inventories Raw materials and stores, work in progress and finished goods Raw materials and stores, work in progress and finished goods are stated at the lower of cost and net realizable value. Cost comprises direct materials, direct labour and an appropriate proportion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Costs are assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased inventory are determined after deducting rebates and discounts. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.
Investments and other financial assets	(n) Investments and other financial assets (i) Classification The group classifies its financial assets in the following measurement categories: ● those to be measured subsequently at fair value (either through other comprehensive income or through profit or loss); and ● those to be measured at amortized cost. The classification depends on the group’s business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses will either be recorded in profit or loss and other comprehensive income. For investments in equity instruments that are not held for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI). (ii) Recognition and derecognition Regular way purchases and sales of financial assets are recognized on trade-date, the date on which the group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has transferred substantially all the risks and rewards of ownership. (iii) Measurement At initial recognition, the group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss. (v) Income recognition - Interest income Interest income is recognized using the effective interest method. When a receivable is impaired, the group reduces the carrying amount to its recoverable amount, being the estimated future cash flow discounted at the original effective interest rate of the instrument, and continues unwinding the discount as interest income. Interest income on impaired loans is recognized using the original effective interest rate.
Property, plant and equipment	(o) Property, plant and equipment Property, plant and equipment is stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred. Depreciation is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements and certain leased plant and equipment, the shorter of the useful life of the asset and the term of lease as follows: ● Plant and equipment 2 - 5 years ● Furniture, fittings and equipment 3 - 15 years ● Right-of-use assets 3 years The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount. Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss.
Intangible assets	(p) Intangible assets Research and development Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense when it is incurred. Expenditure on development activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved products or services before the start of commercial production or use, is capitalized if it is probable that the product or service is technically and commercially feasible, will generate probable economic benefits, adequate resources are available to complete development and cost can be measured reliably. Other development expenditure is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense as incurred.
Trade and other payables	(q) Trade and other payables These amounts represent liabilities for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.
Employee benefits	(r) Employee benefits (i) Short-term obligations Liabilities for wages and salaries, including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet. (ii) Other long-term employee benefit obligations In some countries, the group also has liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. These obligations are therefore measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the end of the reporting period of high-quality corporate bonds with terms and currencies that match, as closely as possible, the estimated future cash outflows. Remeasurements as a result of experience adjustments and changes in actuarial assumptions are recognized in profit or loss. The obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur. (iii) Share-based payments Share-based compensation benefits are provided to employees via the Omnibus Incentive Plan (OIP). Employee options The fair value of options granted under the OIP is recognized as a share-based payment expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted: - including any market performance conditions (e.g. the company’s share price); - excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the company over a specified time period); and - including the impact of any non-vesting conditions (e.g. the requirement for employees to save or holdings shares for a specific period of time). The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the entity revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. It recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.
Contributed equity	(s) Contributed equity Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.
Loss per share	(t) Loss per share (i) Basic loss per share Basic loss per share is calculated by dividing: ● the loss attributable to owners of the company, excluding any costs of servicing equity other than ordinary shares ● by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year. (ii) Diluted loss per share Diluted loss per share adjusts the figures used in the determination of basic loss per share to take into account: ● the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and ● the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.
Rounding of amounts	(u) Rounding of amounts The company is of a kind referred to in ASIC Legislative Instrument 2016/191, relating to the ‘rounding off’ of amounts in the financial statements. Amounts in the financial statements have been rounded off in accordance with the instrument to the nearest dollar.
Goods and services tax (GST)	(v) Goods and services tax (GST) Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated balance sheet. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the taxation authority, are presented as operating cash flows.
Parent entity financial information	(w) Parent entity financial information The financial information for the parent entity, Immuron Limited, disclosed in Note 21 has been prepared on the same basis as the consolidated financial statements, except that accounted for at cost in the financial statements of Immuron Limited.

Revenue and other income (Table

Revenue and other income (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Revenue Text Block Abstract
Schedule of revenue and other income	30 June 30 June 30 June A$ A$ A$ Revenue Revenue from Operating Activities Revenue from contracts with customers 765,193 145,776 2,518,566 Total Revenue from Operating Activities 765,193 145,776 2,518,566 Other Income Australian R&D tax incentive refund 257,500 356,209 308,225 COVID-19 government assistance - 161,600 154,904 HJF R&D grant 306,595 74,821 - MTEC R&D grant 369,045 - - Other income 24,585 24,480 10,545 Total Other Income 957,725 617,110 473,674 Other Gains/(Losses) – Net Net foreign exchange gains/(losses) 247,558 (582,528 ) 11,335 Net impairment losses - (759,765 ) -

Expenses (Tables)

Expenses (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Expenses By Nature Text Block Abstract
Schedule of expenses	30 June 30 June 30 June General and administrative expenses Accounting and audit 499,331 547,055 389,798 Bad debts - 5,472 26,983 Consulting 226,710 126,215 181,474 Depreciation 42,606 43,662 44,056 Employee benefits 1,212,721 1,775,809 1,531,037 Expected credit losses 8,809 (30,055 ) (3,991 ) Insurance 401,121 341,202 469,844 Investor relations 38,567 38,568 197,839 Legal 520,698 205,722 184,382 Listing and share registry 164,949 292,113 212,236 Occupancy - - 51,973 Superannuation 62,647 41,964 48,877 Travel and entertainment 9,459 1,398 91,347 Share-based payment expenses 94,890 2,116,013 (533,912 ) Other 241,880 589,554 278,135 3,524,388 6,094,692 3,170,078 Research and development expenses Consulting 230,684 1,006,086 262,720 Project research and development 427,031 360,968 915,965 657,715 1,367,054 1,178,685 Selling and marketing expenses Selling 57,854 25,858 340,046 Marketing 113,472 90,652 295,261 Distribution costs 245,211 171,174 236,244 416,537 287,684 871,551

Income Tax Expense (Tables)

Income Tax Expense (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Income Tax Text Block Abstract
Schedule of unused tax losses for which no deferred tax asset recognized	30 June 30 June Unused tax losses for which no deferred tax asset has been recognized 48,058,129 44,178,579 Potential tax benefit 25% (2021: 26%) 12,014,532 11,486,431
Schedule of income tax expense	30 June 30 June Loss from continuing operations before income tax expense (2,854,254 ) (8,384,465 ) Tax at the Australian tax rate of 25% (2021: 26%) (713,564 ) (2,179,961 ) Tax effect of amounts which are not deductible (taxable) in calculating taxable income: R&D tax incentive (64,375 ) (92,614 ) Accounting expenditure subject to R&D tax incentive 147,989 212,907 Share-based payments 23,723 550,163 Net impact of other amounts not deductible (taxable) (363,661 ) 428,003 Subtotal (969,888 ) (1,081,502 ) Tax losses and other timing differences for which no deferred tax asset is recognized 969,888 1,081,502 Income tax expense - -

Key Management Personnel Comp_2

Key Management Personnel Compensation (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Information About Key Management Personnel Text Block Abstract
Schedule of key management personnel compensation	30 June 30 June 30 June A$ A$ A$ Key Management Personnel Compensation Short-term employee benefits 636,673 450,002 867,054 Other short-term benefits, including consulting services by KMP and their related entities — 1,603,747 — Post-employment benefits 44,489 27,869 29,213 Long-term benefits 15,168 8,220 3,610 Share-based payment expenses to KMP and their related entities 94,890 2,116,012 73,088 Total Key Management Personnel Compensation 791,220 4,205,850 972,965

Loss per Share (Tables)

Loss per Share (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Earnings Per Share Text Block Abstract
Schedule of basic and diluted loss per share	30 June 30 June 30 June A$ A$ A$ Basic/Diluted loss per share (in cents) 1.25 3.79 1.66 a) Net loss used in the calculation of basic and diluted loss per share 2,854,254 8,384,465 2,927,206 b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share 227,579,684 221,062,229 176,393,354

Financial assets and financia_2

Financial assets and financial liabilities (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Redesignated Financial Assets And Liabilities Text Block Abstract
Schedule of cash and cash equivalents	30 June 30 June A$ A$ Cash at Bank and in hand: Cash at bank and in hand 22,110,278 25,047,281 Total 22,110,278 25,047,281
Schedule of trade and other receivables	30 June 30 June A$ A$ Current Trade receivables 1 217,154 28,553 Loss allowance (8,809 ) - Accrued income – Australian R&D tax incentive refund 2 257,500 306,154 Other income receivables – R&D grants 3 197,051 - Total 662,896 334,707 1 All trade receivables are non-interest bearing. 2 Receivables from the Australian Tax Office in relation to R&D tax incentive refund for the year. 3 As at 30 June 2022, the group has other income receivables of $100,328 R&D grant from the Henry M Jackson Foundation (“HJF”) and $96,723 R&D grant from Medical Technology Enterprise Consortium (“MTEC”).
Schedule of other current assets	30 June 30 June A$ A$ Prepayment 572,400 78,258 Total 572,400 78,258
Schedule of trade and other payables	30 June 30 June Current Trade payables 720,867 106,893 Accrued expenses 411,913 625,980 Other payables 28,113 25,621 Total 1,160,893 758,494

Non-financial assets and liab_2

Non-financial assets and liabilities (Tables)	12 Months Ended
	Jun. 30, 2022
Nonfinancial Assets And Liabilities Abstract
Schedule of property, plant and equipment	Non-current Plant and equipment Furniture, fittings and equipment Right-of-use assets Total At 1 July 2020 Cost or fair value 348,178 35,042 115,977 499,197 Accumulated depreciation (336,051 ) (34,491 ) (57,882 ) (428,424 ) Net book amount 12,127 551 58,095 70,773 Year ended 30 June 2021 Opening net book amount 12,127 551 58,095 70,773 Additions 6,630 - - 6,630 Depreciation charge (4,761 ) (277 ) (38,624 ) (43,662 ) Closing net book amount 13,996 274 19,471 33,741 Non-current Plant and equipment Furniture, fittings and equipment Right-of-use assets Total At 30 June 2021 Cost or fair value 354,808 35,042 115,977 505,827 Accumulated depreciation (340,812 ) (34,768 ) (96,506 ) (472,086 ) Net book amount 13,996 274 19,471 33,741 Plant and equipment Furniture, fittings and equipment Right-of-use assets Total Year ended 30 June 2022 Opening net book amount 13,996 274 19,471 33,741 Additions 10,048 - - 10,048 Lease modification - - 209,560 209,560 Depreciation charge (4,531 ) (137 ) (21,945 ) (26,613 ) Closing net book amount 19,513 137 207,086 226,736 At 30 June 2022 Cost or fair value 364,856 35,042 229,031 628,929 Accumulated depreciation and impairment (345,343 ) (34,905 ) (21,945 ) (402,193 ) Net book amount 19,513 137 207,086 226,736
Schedule of inventories	30 June 30 June Current Non- Total Current Non- Total Raw materials and stores (Colostrum) 137,206 956,936 1,094,142 - 1,266,587 1,266,587 Work in progress 124,412 - 124,412 - - - Finished goods (Travelan and Protectyn) 64,923 - 64,923 292,532 - 292,532 Other inventories 37 - 37 - - - 326,578 956,936 1,283,514 292,532 1,266,587 1,559,119
Schedule of employee benefit obligations	2022 2021 Current Non- Total Current Non- Total Leave obligations (i) 211,776 36 211,812 129,837 36,196 166,033
Schedule of leases in balance sheet	30 June 30 June Right-of-use assets 1 Properties 207,086 19,471 207,086 19,471 Lease liabilities 2 Current 34,376 20,498 Non-current 175,411 - 209,787 20,498
Schedule of statement of profit or loss	2022 2021 Depreciation charge of right-of-use assets Properties 37,937 38,624 37,937 38,624 Interest expense (included in finance cost) 6,100 1,152 Expense relating to short-term leases (included in other expenses) - Expense relating to leases of low-value assets that are not short-term leases (included in other expenses) - Expense relating to variable lease payments not included in lease liabilities (included in other expenses) - Cash paid for principal payments 36,264 40,607

Controlled Entities (Tables)

Controlled Entities (Tables)	12 Months Ended
	Jun. 30, 2022
Controlled Entities Abstract
Schedule of subsidiaries	Percentage of Country of 30 June 30 June Parent Entity: Immuron Limited Australia — — Subsidiaries of Immuron Limited: Immuron Inc. USA 100 % 100 % Anadis EPS Pty Ltd Australia 100 % 100 % IMC Canada Ltd. Canada 100 % 100 %

Provision for Sales Returns (Ta

Provision for Sales Returns (Tables)	12 Months Ended
	Jun. 30, 2022
Description Of Accounting Policy For Provisions Text Block Abstract
Schedule of provision for sales returns	2022 2021 Sales return provision due to the ongoing COVID-19 pandemic Carrying amount at the start of the year 213,024 - Sales return provision recognized 71,025 213,024 Sales return made during the year (188,118 ) - Carrying amount at the end of the year 95,931 213,024

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Classes Of Share Capital Text Block Abstract
Schedule of share capital	2022 2021 2020 2022 2021 2020 Ordinary shares Fully paid 227,798,346 227,246,596 178,279,566 88,436,263 88,361,303 62,426,991 227,798,346 227,246,596 178,279,566 88,436,263 88,361,303 62,426,991
Schedule of ordinary shares	Details Number of shares Total Balance at 30 June 2019 163,215,706 60,289,875 Issue at US$0.10 pursuant to ADS public offering (2019-07-19) 13,565,200 1,926,186 Issue at A$0.16 in lieu of payment for services (2019-11-12) 1 437,500 100,978 Exercise of NASDAQ Warrants (2020-06-23) 86,240 72 Exercise of representative warrants (2020-06-15, 2020-06-22) 974,920 540,062 Transaction costs arising on representative warrants issued — (55,454 ) Less: Transaction costs arising on share issues — (374,728 ) Balance at 30 June 2020 178,279,566 62,426,991 Exercise of representative warrants (2020-07-02) 5,720 - Issue at US$0.47 pursuant to ADS public offering (2020-07-24) 42,666,720 28,165,836 Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24) 100,000 50,000 Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27) 3,008,000 1,051,626 Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29) 40,000 13,959 Transfer from reserves on exercise of ESOP unlisted options (2020-07-24) - 15,700 Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29) - 1,012 Issue at A$0.08 in lieu of cash for services rendered (2020-11-13) 2,737,500 219,000 Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09) 409,090 197,010 Less: Transaction costs arising on share issues - (3,779,831 ) Balance at 30 June 2021 227,246,596 88,361,303 Issue at $0.12 under ESOP Plan (2021-11-05) 333,000 39,960 Issue at $0.16 in lieu of payment for services (2021-12-17) 218,750 35,000 Less: Transaction costs arising on share issues - - Balance at 30 June 2022 227,798,346 88,436,263

Other Reserves (Tables)

Other Reserves (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Reserves Within Equity Text Block Abstract
Schedule of other reserves	Notes Share-based Foreign Total other At 1 July 2019 4,281,790 18,529 4,300,319 Currency translation differences - 102,938 102,938 Other comprehensive income - 102,938 102,938 Transactions with owners in their capacity as owners Share-based payment expenses 16(iv) 73,088 - 73,088 Options and warrants issued/expensed (484,680 ) - (484,680 ) Options and warrants lapsed/expired (2,251,320 ) - (2,251,320 ) Remeasurement of options issued in prior period 16(iii) (607,000 ) - (607,000 ) At 30 June 2020 1,011,878 121,467 1,133,345 Notes Share-based Foreign Total other At 1 July 2020 1,011,878 121,467 1,133,345 Currency translation differences - (14,953 ) (14,953 ) Other comprehensive income - (14,953 ) (14,953 ) Transactions with owners in their capacity as owners Transfer to share capital 16(iv) (73,088 ) - (73,088 ) Options and warrants issued/expensed 16(ii) 3,003,060 - 3,003,060 Options and warrants exercised 16(ii) (213,722 ) - (213,722 ) Options and warrants forfeited (368,000 ) - (368,000 ) At 30 June 2021 3,360,128 106,514 3,466,642 Notes Share-based Foreign Total other At 1 July 2021 3,360,128 106,514 3,466,642 Currency translation differences - 6,708 6,708 Other comprehensive income - 6,708 6,708 Transactions with owners in their capacity as owners Options and warrants issued/expensed 16(ii) 54,930 - 54,930 Options and warrants lapsed/expired (361,861 ) - (361,861 ) At 30 June 2022 3,053,197 113,222 3,166,419
Schedule of movements in options and warrants	Details Notes Number of options Total Balance at 30 June 2019 79,463,744 4,281,790 Remeasurement of options issued in prior period (2019-11-06) 16(iii) - (607,000 ) Issue of representative warrants (2019-07-16) 542,600 55,454 Lapse of unexercised options at $0.50 (2019-11-27) (7,625,532 ) (2,086,920 ) Lapse of unexercised options at $0.55 (2019-11-30) (25,289,894 ) - Lapse of unexercised options at $0.50 (2020-06-30) (2,000,000 ) (164,400 ) Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23) (218,800 ) (72 ) Exercise of representative warrants (2020-06-15, 2020-06-22) (2,065,000 ) (540,062 ) Share-based payments expenses - 73,088 Balance at 30 June 2020 42,807,118 1,011,878 Exercise of representative warrants (2020-07-2) (9,640 ) - Exercise of ESOP unlisted options at $0.50 (2020-07-24) (100,000 ) (15,700 ) Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29) (3,048,000 ) (1,012 ) Lapse of unexercised options (2020-09-25) (5,000,000 ) (368,000 ) Issue of representative warrants at US$23.44 per 40 options (2020-07-24) 2,560,000 1,032,960 Issue of ESOP unlisted options at $0.12 (2020-10-29) 9,000,000 1,970,100 Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09) (900,000 ) (197,010 ) Reclassify share-based payments expenses from reserves to share capital 16(iv) - (73,088 ) Balance at 30 June 2021 45,309,478 3,360,128 Lapse of unexercised options at $0.50 (2021-07-01) (1,200,000 ) (188,400 ) Issue of ESOP unlisted options at $0.25 (2021-11-05) 500,000 18,624 Lapse of unexercised options at $1.94 (2021-11-30) (14,493 ) (28,813 ) Lapse of unexercised options at $1.94 (2022-06-14) (24,721,108 ) (144,648 ) ESOP unlisted options granted at $0.12 (2022-06-27) - 36,306 Balance at 30 June 2022 19,873,877 3,053,197

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Entitys Operating Segments Text Block Abstract
Schedule of segment information for the reportable segments	Research Hyperimmune products Other Total 2022 A$ A$ A$ A$ Hyperimmune products revenue - 765,193 - 765,193 Cost of sales of goods - (241,691 ) - (241,691 ) Gross profit - 523,502 - 523,502 Other income 933,140 24,585 - 957,725 Net foreign exchange gains/(losses) - - 247,558 247,558 General and administrative expenses - (164,087 ) (3,360,301 ) (3,524,388 ) Research and development expenses (657,715 ) - - (657,715 ) Selling and marketing expenses - (416,537 ) - (416,537 ) Operating profit/(loss) 275,425 (32,537 ) (3,112,743 ) (2,869,855 ) Finance income - - 21,785 21,785 Finance costs - - (6,184 ) (6,184 ) Income tax expense - - - - Profit/(loss) for the year 275,425 (32,537 ) (3,097,142 ) (2,854,254 ) Assets Segment assets 257,500 1,688,910 22,909,414 24,855,824 Total assets 257,500 1,688,910 22,909,414 24,855,824 Liabilities Segment liabilities 7,053 150,151 1,521,219 1,678,423 Total liabilities 7,053 150,151 1,521,219 1,678,423 Research Hyperimmune Other Total 2021 A$ A$ A$ A$ Hyperimmune products revenue - 145,776 - 145,776 Cost of sales of goods - (51,071 ) - (51,071 ) Gross profit - 94,705 - 94,705 Other income 431,030 24,480 161,600 617,110 Net foreign exchange gains/(losses) - - (582,528 ) (582,528 ) Net impairment losses - (759,765 ) - (759,765 ) General and administrative expenses - - (6,094,692 ) (6,094,692 ) Research and development expenses (1,367,054 ) - - (1,367,054 ) Selling and marketing expenses - (287,684 ) - (287,684 ) Operating profit/(loss) (936,024 ) (928,264 ) (6,515,620 ) (8,379,908 ) Finance income - - 9,204 9,204 Finance costs - - (13,761 ) (13,761 ) Income tax expense - - - - Profit/(loss) for the year (936,024 ) (928,264 ) (6,520,177 ) (8,384,465 ) Assets Segment assets 306,154 1,587,672 25,159,280 27,053,106 Total assets 306,154 1,587,672 25,159,280 27,053,106 Liabilities Segment liabilities 243,565 284,657 629,827 1,158,049 Total liabilities 243,565 284,657 629,827 1,158,049 Research Hyperimmune Other Total 2020 A$ A$ A$ A$ Hyperimmune products revenue - 2,518,566 - 2,518,566 Cost of sales of goods - (688,836 ) - (688,836 ) Gross profit - 1,829,730 - 1,829,730 Other income 308,225 10,545 154,904 473,674 Net foreign exchange gains/(losses) - - 11,335 11,335 General and administrative expenses - - (3,170,078 ) (3,170,078 ) Research and development expenses (1,178,685 ) - - (1,178,685 ) Selling and marketing expenses - (871,551 ) - (871,551 ) Operating profit/(loss) (870,460 ) 968,724 (3,003,839 ) (2,905,575 ) Finance income - - - - Finance costs - - (21,631 ) (21,631 ) Income tax expense - - - - Profit/(loss) for the year (870,460 ) 968,724 (3,025,470 ) (2,927,206 ) Assets Segment assets 308,225 2,539,503 3,354,435 6,202,163 Total assets 308,225 2,539,503 3,354,435 6,202,163 Liabilities Segment liabilities 101,092 30,377 426,781 558,250 Total liabilities 101,092 30,377 426,781 558,250
Schedule of information on geographical regions	Travelan Protectyn Australia United States Canada Australia Total 2022 A$ A$ A$ A$ A$ Hyperimmune products revenue 143,378 501,228 63,172 57,415 765,193 Revenue from external customers 143,378 501,228 63,172 57,415 765,193 Travelan Protectyn Australia United States Canada Australia Total 2021 A$ A$ A$ A$ A$ Hyperimmune products revenue 1 (10,308 ) 4,264 101,639 50,181 145,776 Revenue from external customers (10,308 ) 4,264 101,639 50,181 145,776 Travelan Protectyn Australia United States Canada Australia Total 2020 A$ A$ A$ A$ A$ Hyperimmune products revenue 1,240,393 926,325 301,915 49,933 2,518,566 Revenue from external customers 1,240,393 926,325 301,915 49,933 2,518,566
Schedule of major customers	2022 A$ 2021 A$ 2020 A$ Customer A 263,137 - 327,559 Customer B 253,803 23,214 462,490 Customer C 99,792 - 438,065 Customer D - - 442,916 Customer E - - 227,952 Customer F - 41,040 - Customer G - 27,563 - Customer H - 25,319 - Customer I - 22,886 - 616,732 140,022 1,898,982

Cash Flow Information (Tables)

Cash Flow Information (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Cash Flow Information Explanatory Abstract
Schedule of reconciliation of cash flow from operations with loss after income tax	30 June 30 June 30 June Net Loss for the Year (2,854,254 ) (8,384,465 ) (2,927,206 ) Adjustments for Depreciation expense 26,613 43,662 44,056 Lease modification 15,993 - - Distribution costs 35,000 - 70,000 Expected credit losses 8,809 (30,055 ) (3,991 ) Finance costs 6,184 13,761 21,631 Finance income (21,785 ) (9,204 ) - Leave provision expense 45,470 53,610 19,717 Share-based payments (income)/expenses 94,891 2,116,013 (533,912 ) Unrealized net foreign currency gains (234,794 ) 592,243 (18,883 ) Change in operating assets and liabilities: Add decrease in trade and other receivables (336,998 ) 23,037 641,236 Add (increase) / decrease in inventories 275,605 960,920 (113,635 ) Add (increase) / decrease in other operating assets (494,143 ) (45,065 ) 16,096 Add (decrease) / increase in trade and other payables 285,616 586,796 (362,437 ) (3,147,793 ) (4,078,747 ) (3,147,328 )

Share-based Payments (Tables)

Share-based Payments (Tables)	12 Months Ended
	Jun. 30, 2022
Share-based Payments (Tables) [Line Items]
Schedule of share options outstanding	Exercise Share Share Share Grant date Expiry (A$ unless 30 June 30 June 30 June 2012-06-29 2021-11-30 1.944 - 14,493 14,493 2012-06-29 2022-01-17 1.876 - 29,668 29,668 2017-06-13 (warrants) 2022-06-13 USD 0.25 - 24,493,200 27,541,200 2018-03-15 2023-03-15 0.468 7,897,647 7,897,647 7,897,647 2017-06-09 (warrants) 2022-06-08 USD 0.3125 198,240 198,240 2018-03-15 2023-03-15 0.585 526,510 526,510 526,510 2019-05-23 (warrants) 2024-05-23 USD 0.125 173,600 173,600 181,600 2019-07-16 (warrants) 2024-07-16 USD 0.125 116,120 116,120 117,760 2018-07-13 2021-07-01 0.500 - 1,200,000 1,300,000 2019-11-06 2024-02-10 0.500 - - 5,000,000 2020-10-29 2024-04-14 0.12 8,100,000 8,100,000 - 2020-07-24 (warrants) 2025-07-21 USD 0.5859 2,560,000 2,560,000 - 2021-10-26 2025-10-26 0.25 500,000 - - Total 19,873,877 45,309,478 42,807,118 Weighted average remaining contractual life of options outstanding at end of period 1.54 1.58 2.28
Schedule of total expenses arising from share-based payment transactions	2022 2021 2020 1 Options issued under OIP 54,930 1,970,100 (607,000 ) Shares issued under OIP 39,960 - - Share-based payments to KMP 2 - 145,913 73,088 94,890 2,116,013 (533,912 )
ESOP [Member]
Share-based Payments (Tables) [Line Items]
Schedule of movement in number of stock options outstanding and weighted average exercise price	2022 2021 2020 Average Number of Average Number of options Average Number of As at 1 July 0.31 45,309,478 0.40 42,807,118 0.46 79,463,744 Granted during the year 0.25 500,000 0.28 11,560,000 0.18 542,600 Exercised during the year - - 0.23 (4,057,640 ) 0.18 (424,840 ) Forfeited/lapsed during the year 0.27 (25,935,601 ) 0.50 (5,000,000 ) 0.52 (36,774,386 ) As at 30 June 0.37 19,873,877 0.31 45,309,478 0.40 42,807,118 Vested and exercisable at 30 June 0.37 19,538,877 0.31 45,309,478 0.40 42,807,118
Schedule of granted valuation of options	Grant date Expiry date Exercise No. of Share price Expected Dividend Risk- free Fair value 2021-10-26 2025-10-26 0.25 500,000 0.12 131.70 % 0.00 % 0.69 % 0.0886 2022-06-27 2026-06-27 0.12 1,430,000 * 0.07 128.10 % 0.00 % 3.31 % 0.0530 1,930,000 Grant date Expiry date Exercise price No. of Share price Expected Dividend Risk- free Fair value 2020-07-24 2025-07-21 0.83 2,560,000 0.50 127.93 % 0.00 % 0.43 % 0.4035 2020-10-29 2024-04-14 0.12 9,000,000 0.25 142.70 % 0.00 % 0.13 % 0.2189 11,560,000 Grant date Expiry date Exercise No. of Share price Expected Dividend Risk- free Fair value 2019-11-06 2024-02-10 0.50 5,000,000 * 0.15 98 0.00 % 0.88 % 0.0736 5,000,000 * Options issued to a former managing director expire within 6 months upon his resignation on 25 March 2020 without good reason or termination.

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Related Party Text Block Abstract
Schedule of information about other related party transactions	2022 2021 2020 Amounts settled in cash or shares for goods and services Purchases of various goods and services from entities controlled by key management personnel (i) 154,364 110,607 142,347 Legal services by key management personnel (ii) 20,000 - - 2021 2021 2020 Amounts settled in cash or shares during the period Rental of an office suite from Wattle Laboratories Pty Ltd 42,364 40,607 41,369 Services rendered by Grandlodge Capital Pty Ltd 112,000 70,000 100,978 154,364 110,607 142,347
Schedule of outstanding balances transactions with related parties	2022 A$ 2021 A$ 2020 A$ Current payables (purchases of goods and services) Entities controlled by key management personnel 77,000 70,000 -

Financial Risk Management Obj_2

Financial Risk Management Objectives and Policies (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Financial Risk Management Text Block Abstract
Schedule of foreign currency risk	2022 2021 USD CAD ILS USD CAD ILS Cash and cash equivalents 3,138,079 29,224 - 108,688 2,742,688 108,688 - Trade receivables 279,986 - - - 23,801 - - Trade payables 73,430 803 2,240 43,466 18,556 43,466 - Total exposure 3,491,495 30,027 2,240 152,154 2,785,045 152,154 -
Schedule of exchange rates	Impact on loss for Impact on other 2022 2021 2022 2021 USD/AUD exchange rate – change by 5.8% (2021: 4.9%) 202,507 136,467 6,567 5,219
Schedule of trade receivables	Days past due Current 1-30 31-60 61-90 91-120 121+ Total 30 June 2022 A$ A$ A$ A$ A$ A$ A$ Expected credit loss rate 0.00 % 0.00 % 13.08 % 24.14 % 26.84 % 0.00 % Gross carrying amount - - 7,959 664 186 - 8,809 Loss allowance - - - - - - - Days past due 30 June 2021 Current 1-30 31-60 61-90 91-120 121+ Total Expected credit loss rate 0.00 % 0.00 % 13.07 % 21.88 % 34.09 % 53.58 % Gross carrying amount 23,801 4,752 - - - - 28,553 Loss allowance - - - - - - -
Schedule of contractual discounted cash flows	Contractual maturities Less than 6 months 6 - 12 Between Between Over Total contractual Carrying At 30 June 2022 A$ A$ A$ A$ A$ A$ A$ Trade and other payables 748,980 - - - - 748,980 748,980 Lease liabilities 34,376 - - - - 34,376 34,376 Total 748,980 - - - - 748,980 748,980 At 30 June 2021 Trade and other payables 132,514 - - - - 132,514 132,514 Lease liabilities 20,498 - - - - 20,498 20,498 Total 153,012 - - - - 153,012 153,012

Parent Entity Financial Infor_2

Parent Entity Financial Information (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Parent Entity Financial Information Abstract
Schedule of individual financial statements for the parent entity	2022 2021 Balance sheet Current assets 23,685,902 25,698,082 Non-current assets 1,181,517 1,300,467 Total assets 24,867,419 26,998,549 Current liabilities 1,498,834 1,118,020 Non-current liabilities 175,447 36,196 Total liabilities 1,674,281 1,154,216 (46,386,276 ) (51,688,666 ) Shareholders' equity Share capital 88,436,263 88,361,303 Reserves Share-based payments 3,053,197 3,360,128 Accumulated losses (68,296,322 ) (65,877,098 ) 23,193,138 25,844,333 Loss for the year 2,781,085 8,271,111 Total comprehensive loss 2,781,085 8,271,111

Auditors' Remuneration (Tables)

Auditors' Remuneration (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Auditors Remuneration Text Block Abstract
Schedule of auditors' remuneration for each of the years indicated, the fees billed by Grant Thornton Audit Pty Ltd	Year Ended June 30, 2022 2021 Audit and review of financial statements (1) 173,631 179,742 173,631 179,742 (1) Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant can reasonably provide.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Summary of Significant Accounting Policies (Details) [Line Items]
Rebates percentage	10%
Plant and Equipment [Member] | Bottom of range [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	2 years
Plant and Equipment [Member] | Top of range [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	5 years
Furniture, fittings and equipment [Member] | Bottom of range [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	3 years
Furniture, fittings and equipment [Member] | Top of range [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	15 years
Right-of-use assets [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	3 years
Henry M Jackson Foundation [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
R&D grant (in Dollars)	$ 306,595	$ 74,821
Medical Technology Enterprise Consortium [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
R&D grant (in Dollars)	$ 369,045

Critical Accounting Estimates_2

Critical Accounting Estimates and Judgments (Details) - USD ($)		12 Months Ended
	Dec. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Accounting Judgements And Estimates Text Block Abstract
Finished goods impairment	$ 218,506		$ 328,833
Impairment of inventories			430,932
Raw materials relating to colostrum
Remaining balance		$ 956,936	1,266,587
Other income		$ 257,500	$ 356,209

Revenue and other income (Detai

Revenue and other income (Details)	12 Months Ended
	Jun. 30, 2022 AUD ($)	Jun. 30, 2021 AUD ($)	Jun. 30, 2021 USD ($)
Disclosure Of Revenue Text Block Abstract
Other income	$ 257,500		$ 356,209
Government assistance packages (in Dollars)		$ 161,600
Group recognized description	For the year ended 30 June 2022, the group has recognized $306,595 (2021: $74,821) R&D grant from the Henry M Jackson Foundation (“HJF”) and $369,045 (2021: Nil) R&D grant from Medical Technology Enterprise Consortium (“MTEC”).
Finished goods impairment			328,833
Impairment of inventories			$ 430,932

Revenue and other income (Det_2

Revenue and other income (Details) - Schedule of revenue and other income - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Revenue from Operating Activities
Revenue from contracts with customers	$ 765,193	$ 145,776	$ 2,518,566
Total Revenue from Operating Activities	765,193	145,776	2,518,566
Other Income
Australian R&D tax incentive refund	257,500	356,209	308,225
COVID-19 government assistance		161,600	154,904
HJF R&D grant	306,595	74,821
MTEC R&D grant	369,045
Other income	24,585	24,480	10,545
Total Other Income	957,725	617,110	473,674
Other Gains/(Losses) – Net
Net foreign exchange gains/(losses)	247,558	(582,528)	11,335
Net impairment losses		$ (759,765)

Expenses (Details) - Schedule o

Expenses (Details) - Schedule of expenses - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
General and administrative expenses
Accounting and audit	$ 499,331	$ 547,055	$ 389,798
Bad debts		5,472	26,983
Consulting	226,710	126,215	181,474
Depreciation	42,606	43,662	44,056
Employee benefits	1,212,721	1,775,809	1,531,037
Expected credit losses	8,809	(30,055)	(3,991)
Insurance	401,121	341,202	469,844
Investor relations	38,567	38,568	197,839
Legal	520,698	205,722	184,382
Listing and share registry	164,949	292,113	212,236
Occupancy			51,973
Superannuation	62,647	41,964	48,877
Travel and entertainment	9,459	1,398	91,347
Share-based payment expenses	94,890	2,116,013	(533,912)
Other	241,880	589,554	278,135
Total general and administrative expenses	3,524,388	6,094,692	3,170,078
Research and development expenses
Consulting	230,684	1,006,086	262,720
Project research and development	427,031	360,968	915,965
Total research and development expenses	657,715	1,367,054	1,178,685
Selling and marketing expenses
Selling	57,854	25,858	340,046
Marketing	113,472	90,652	295,261
Distribution costs	245,211	171,174	236,244
Total selling and marketing expenses	$ 416,537	$ 287,684	$ 871,551

Income Tax Expense (Details) -

Income Tax Expense (Details) - Schedule of unused tax losses for which no deferred tax asset recognized - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Unused Tax Losses For Which No Deferred Tax Asset Recognized Abstract
Unused tax losses for which no deferred tax asset has been recognized	$ 48,058,129	$ 44,178,579
Potential tax benefit @ 25% (2021: 26%)	$ 12,014,532	$ 11,486,431

Income Tax Expense (Details) _2

Income Tax Expense (Details) - Schedule of income tax expense - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Income Tax Expense Abstract
Loss from continuing operations before income tax expense	$ (2,854,254)	$ (8,384,465)	$ (2,927,206)
Tax at the Australian tax rate of 25% (2021: 26%)	(713,564)	(2,179,961)
Tax effect of amounts which are not deductible (taxable) in calculating taxable income:
R&D tax incentive	(64,375)	(92,614)
Accounting expenditure subject to R&D tax incentive	147,989	212,907
Share-based payments	23,723	550,163
Net impact of other amounts not deductible (taxable)	(363,661)	428,003
Subtotal	(969,888)	(1,081,502)
Tax losses and other timing differences for which no deferred tax asset is recognized	969,888	1,081,502
Income tax expense

Key Management Personnel Comp_3

Key Management Personnel Compensation (Details) - Schedule of key management personnel compensation - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Key Management Personnel Compensation
Short-term employee benefits	$ 636,673	$ 450,002	$ 867,054
Other short-term benefits, including consulting services by KMP and their related entities		1,603,747
Post-employment benefits	44,489	27,869	29,213
Long-term benefits	15,168	8,220	3,610
Share-based payment expenses to KMP and their related entities	94,890	2,116,012	73,088
Total Key Management Personnel Compensation	$ 791,220	$ 4,205,850	$ 972,965

Loss per Share (Details) - Sche

Loss per Share (Details) - Schedule of basic and diluted loss per share - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Basic And Diluted Loss Per Share Abstract
Basic/Diluted loss per share (in cents)	$ 1.25	$ 3.79	$ 1.66
a) Net loss used in the calculation of basic and diluted loss per share	$ 2,854,254	$ 8,384,465	$ 2,927,206
b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share	227,579,684	221,062,229	176,393,354

Financial assets and financia_3

Financial assets and financial liabilities (Details)	12 Months Ended
	Jun. 30, 2022 USD ($)
Henry M Jackson Foundation [Member]
Financial assets and financial liabilities (Details) [Line Items]
Other income receivables	$ 100,328
Medical Technology Enterprise Consortium [Member]
Financial assets and financial liabilities (Details) [Line Items]
Other income receivables	$ 96,723

Financial assets and financia_4

Financial assets and financial liabilities (Details) - Schedule of cash and cash equivalents - AUD ($)	Jun. 30, 2022	Jun. 30, 2021
Cash at Bank and in hand:
Cash at bank and in hand	$ 22,110,278	$ 25,047,281
Total	$ 22,110,278	$ 25,047,281

Financial assets and financia_5

Financial assets and financial liabilities (Details) - Schedule of trade and other receivables - AUD ($)		Jun. 30, 2022	Jun. 30, 2021
Schedule Of Trade And Other Receivables Abstract
Trade receivables	[1]	$ 217,154	$ 28,553
Loss allowance		(8,809)
Accrued income – Australian R&D tax incentive refund	[2]	257,500	306,154
Other income receivables – R&D grants	[3]	197,051
Total		$ 662,896	$ 334,707
[1] All trade receivables are non-interest bearing. Receivables from the Australian Tax Office in relation to R&D tax incentive refund for the year. As at 30 June 2022, the group has other income receivables of $100,328 R&D grant from the Henry M Jackson Foundation (“HJF”) and $96,723 R&D grant from Medical Technology Enterprise Consortium (“MTEC”).

Financial assets and financia_6

Financial assets and financial liabilities (Details) - Schedule of other current assets - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Other Current Assets Abstract
Prepayment	$ 572,400	$ 78,258
Total	$ 572,400	$ 78,258

Financial assets and financia_7

Financial assets and financial liabilities (Details) - Schedule of trade and other payables - AUD ($)	Jun. 30, 2022	Jun. 30, 2021
Current
Trade payables	$ 720,867	$ 106,893
Accrued expenses	411,913	625,980
Other payables	28,113	25,621
Total	$ 1,160,893	$ 758,494

Non-financial assets and liab_3

Non-financial assets and liabilities (Details) - USD ($)		12 Months Ended
	Dec. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Nonfinancial Assets And Liabilities Abstract
No finished goods impairment	$ 218,506		$ 328,833
No raw materials impairment of inventories			430,932
Total leave provision		$ 211,776
Total leave provision in current			129,837
Leases outflow cash		$ 6,100	$ 1,152

Non-financial assets and liab_4

Non-financial assets and liabilities (Details) - Schedule of property, plant and equipment - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Jul. 01, 2020
Cost or fair value [Member]
Non-financial assets and liabilities (Details) - Schedule of property, plant and equipment [Line Items]
Plant and equipment	$ 364,856	$ 354,808	$ 348,178
Furniture, fittings and equipment	35,042	35,042	35,042
Right-of-use assets	229,031	115,977	115,977
Total	628,929	505,827	499,197
Accumulated depreciation [Member]
Non-financial assets and liabilities (Details) - Schedule of property, plant and equipment [Line Items]
Plant and equipment	(345,343)	(340,812)	(336,051)
Furniture, fittings and equipment	(34,905)	(34,768)	(34,491)
Right-of-use assets	(21,945)	(96,506)	(57,882)
Total	(402,193)	(472,086)	(428,424)
Net book amount [Member]
Non-financial assets and liabilities (Details) - Schedule of property, plant and equipment [Line Items]
Plant and equipment	19,513	13,996	12,127
Furniture, fittings and equipment	137	274	551
Right-of-use assets	207,086	19,471	58,095
Total	226,736	33,741	$ 70,773
Opening net book amount [Member]
Non-financial assets and liabilities (Details) - Schedule of property, plant and equipment [Line Items]
Plant and equipment	13,996	12,127
Furniture, fittings and equipment	274	551
Right-of-use assets	19,471	58,095
Total	33,741	70,773
Additions [Member]
Non-financial assets and liabilities (Details) - Schedule of property, plant and equipment [Line Items]
Plant and equipment	10,048	6,630
Furniture, fittings and equipment
Right-of-use assets
Total	10,048	6,630
Depreciation charge [Member]
Non-financial assets and liabilities (Details) - Schedule of property, plant and equipment [Line Items]
Plant and equipment	(4,531)	(4,761)
Furniture, fittings and equipment	(137)	(277)
Right-of-use assets	(21,945)	(38,624)
Total	(26,613)	(43,662)
Closing net book amount [Member]
Non-financial assets and liabilities (Details) - Schedule of property, plant and equipment [Line Items]
Plant and equipment	19,513	13,996
Furniture, fittings and equipment	137	274
Right-of-use assets	207,086	19,471
Total	226,736	$ 33,741
Adoption of AASB 16 [Member]
Non-financial assets and liabilities (Details) - Schedule of property, plant and equipment [Line Items]
Plant and equipment
Furniture, fittings and equipment
Right-of-use assets	209,560
Total	$ 209,560

Non-financial assets and liab_5

Non-financial assets and liabilities (Details) - Schedule of inventories	Jun. 30, 2022 AUD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 AUD ($)	Jun. 30, 2021 USD ($)
Non-financial assets and liabilities (Details) - Schedule of inventories [Line Items]
Inventories Current	$ 326,578	$ 326,578	$ 292,532	$ 292,532
Inventories Non- current	$ 956,936	956,936	$ 1,266,587	1,266,587
Total Inventories net		1,283,514		1,559,119
Raw materials and stores (Colostrum) [Member]
Non-financial assets and liabilities (Details) - Schedule of inventories [Line Items]
Inventories Current		137,206
Inventories Non- current		956,936		1,266,587
Total Inventories net		1,094,142		1,266,587
Work in progress [Member]
Non-financial assets and liabilities (Details) - Schedule of inventories [Line Items]
Inventories Current		124,412
Inventories Non- current
Total Inventories net		124,412
Finished goods (Travelan and Protectyn) [Member]
Non-financial assets and liabilities (Details) - Schedule of inventories [Line Items]
Inventories Current		64,923		292,532
Inventories Non- current
Total Inventories net		64,923		292,532
Other inventories [Member]
Non-financial assets and liabilities (Details) - Schedule of inventories [Line Items]
Inventories Current		37
Inventories Non- current
Total Inventories net		$ 37

Non-financial assets and liab_6

Non-financial assets and liabilities (Details) - Schedule of employee benefit obligations - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Non-financial assets and liabilities (Details) - Schedule of employee benefit obligations [Line Items]
Leave obligations	$ 211,812	$ 166,033
Current [member]
Non-financial assets and liabilities (Details) - Schedule of employee benefit obligations [Line Items]
Leave obligations	211,776	129,837
Non- current [Member]
Non-financial assets and liabilities (Details) - Schedule of employee benefit obligations [Line Items]
Leave obligations	$ 36	$ 36,196

Non-financial assets and liab_7

Non-financial assets and liabilities (Details) - Schedule of leases in balance sheet - AUD ($)		Jun. 30, 2022	Jun. 30, 2021
Right-of-use assets1
Properties	[1]	$ 207,086	$ 19,471
Total right-of-use assets	[1]	207,086	19,471
Lease liabilities2
Current	[2]	34,376	20,498
Non-current	[2]	175,411
Total lease liabilities		$ 209,787	$ 20,498
[1]Included in the line item ‘property, plant and equipment’ in the consolidated balance sheet.[2]Included in the line items ‘other current liabilities’ and ‘other non-current liabilities’ in the consolidated balance sheet.

Non-financial assets and liab_8

Non-financial assets and liabilities (Details) - Schedule of statement of profit or loss - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Depreciation charge of right-of-use assets
Properties	$ 37,937	$ 38,624
Total	37,937	38,624
Interest expense (included in finance cost)	6,100	1,152
Expense relating to short-term leases (included in other expenses)
Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)
Expense relating to variable lease payments not included in lease liabilities (included in other expenses)
Cash paid for principal payments	$ 36,264	$ 40,607

Controlled Entities (Details) -

Controlled Entities (Details) - Schedule of subsidiaries	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Immuron Limited [Member]
Parent Entity:
Country of Incorporation		Australia
Immuron Inc [Member]
Parent Entity:
Country of Incorporation		USA
Percentage of Ownership	100%	100%
Anadis EPS Pty Ltd [Member]
Parent Entity:
Country of Incorporation		Australia
Percentage of Ownership	100%	100%
IMC Canada Ltd [Member]
Parent Entity:
Country of Incorporation		Canada
Percentage of Ownership	100%	100%

Provision for Sales Returns (De

Provision for Sales Returns (Details) - Schedule of provision for sales returns - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Sales return provision due to the ongoing COVID-19 pandemic
Carrying amount at the start of the year	$ 213,024
Sales return provision recognized	71,025	213,024
Sales return made during the year	(188,118)
Carrying amount at the end of the year	$ 95,931	$ 213,024

Contingent Liabilities and Co_2

Contingent Liabilities and Commitments (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Commitments And Contingent Liabilities Text Block Abstract
Contingent liabilities or commitments

Share Capital (Details)

Share Capital (Details)	12 Months Ended
	Jun. 30, 2022 AUD ($) $ / shares
Disclosure Of Classes Of Share Capital Text Block Abstract
Payment for services | $	$ 70,000
New fully paid ordinary per share | $ / shares	$ 0.16

Share Capital (Details) - Sched

Share Capital (Details) - Schedule of share capital - AUD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Share Capital Abstract
Ordinary shares	227,798,346	227,246,596	178,279,566
Ordinary shares, value	$ 88,436,263	$ 88,361,303	$ 62,426,991
Ordinary shares, Fully paid, shares	227,798,346	227,246,596	178,279,566
Ordinary shares, Fully paid, value	$ 88,436,263	$ 88,361,303	$ 62,426,991

Share Capital (Details) - Sch_2

Share Capital (Details) - Schedule of ordinary shares - AUD ($)		12 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Ordinary Shares Abstract
Balance, shares		227,246,596	178,279,566	163,215,706
Balance		$ 88,361,303	$ 62,426,991	$ 60,289,875
Balance, shares		227,798,346	227,246,596	178,279,566
Balance		$ 88,436,263	$ 88,361,303	$ 62,426,991
Issue at US$0.10 pursuant to ADS public offering (2019-07-19)				13,565,200
Issue at US$0.10 pursuant to ADS public offering (2019-07-19)				$ 1,926,186
Issue at A$0.16 in lieu of payment for services (2019-11-12)	[1]			437,500
Issue at A$0.16 in lieu of payment for services (2019-11-12)	[1]			$ 100,978
Exercise of NASDAQ Warrants (2020-06-23)				86,240
Exercise of NASDAQ Warrants (2020-06-23)				$ 72
Exercise of representative warrants (2020-06-15, 2020-06-22)				974,920
Exercise of representative warrants (2020-06-15, 2020-06-22)				$ 540,062
Transaction costs arising on representative warrants issued
Transaction costs arising on representative warrants issued				$ (55,454)
Exercise of representative warrants (2020-07-02)			5,720
Exercise of representative warrants (2020-07-02)
Issue at US$0.47 pursuant to ADS public offering (2020-07-24)			42,666,720
Issue at US$0.47 pursuant to ADS public offering (2020-07-24)			$ 28,165,836
Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)			100,000
Issue at $0.50 on exercise of ESOP unlisted options (2020-07-24)			$ 50,000
Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)			3,008,000
Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-27)			$ 1,051,626
Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)			40,000
Issue at US$0.25 on exercise of NASDAQ Warrants (2020-07-29)			$ 13,959
Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)
Transfer from reserves on exercise of ESOP unlisted options (2020-07-24)			$ 15,700
Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)
Transfer from reserves on exercise of NASDAQ Warrants (2020-07-27, 2020-07-29)			$ 1,012
Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)			2,737,500
Issue at A$0.08 in lieu of cash for services rendered (2020-11-13)			$ 219,000
Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)			409,090
Transfer from reserves on cashless exercise of ESOP unlisted options (2021-02-09)			$ 197,010
Issue at $0.12 under ESOP Plan (2021-11-05)		333,000
Issue at $0.12 under ESOP Plan (2021-11-05)		$ 39,960
Issue at $0.16 in lieu of payment for services (2021-12-17)		218,750
Issue at $0.16 in lieu of payment for services (2021-12-17)		$ 35,000
Less: Transaction costs arising on share issues
Less: Transaction costs arising on share issues			$ (3,779,831)	$ (374,728)
[1]Mr Peter Anastasiou (resigned 24 September 2021) and Mr Stephen Anastasiou are directors and majority shareholders of Grandlodge Capital Pty Ltd (Grandlodge). As per an agreement which commenced on 1 June 2013 and expired on 30 June 2020, Immuron Limited contracted Grandlodge on normal commercial terms and conditions to provide warehousing, distribution and invoicing services for Immuron Limited’s products for A$70,000 per annum. These fees would be payable in new fully paid ordinary shares in Immuron Limited at a set price of A$0.16 per share, representing Immuron Limited’s shares price at the commencement of the agreement. The above amount is the fair value of the equity instrument.

Other Reserves (Details)

Other Reserves (Details)				1 Months Ended
	Jul. 27, 2022 $ / shares shares	Nov. 05, 2021 $ / shares shares	Oct. 29, 2020 shares	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2021 AUD ($)
Other Reserves (Details) [Line Items]
Stock options issued | shares			9,000,000
Revaluation financials amount				$ 607,000
Value of shares owed						$ 73,088
Dr. Jerry Kanellos [Member]
Other Reserves (Details) [Line Items]
Number of shares unlisted option | shares		500,000
Unlisted option exercisable per shares | $ / shares		$ 0.25
Mr. Richard J. Berman [Member]
Other Reserves (Details) [Line Items]
Number of shares unlisted option | shares	1,430,000
Unlisted option exercisable per shares | $ / shares	$ 0.12
Dr. Gary S. Jacob [Member]
Other Reserves (Details) [Line Items]
Options granted					$ 975,000
Revaluation of options value					$ 368,000

Other Reserves (Details) - Sche

Other Reserves (Details) - Schedule of other reserves - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Other Reserves (Details) - Schedule of other reserves [Line Items]
Balance	$ 3,466,642	$ 1,133,345	$ 4,300,319
Other comprehensive income	6,708	(14,953)	102,938
Share-based payment expenses			73,088
Transfer to share capital		(73,088)
Options and warrants issued/expensed	54,930	3,003,060	(484,680)
Options and warrants exercised		(213,722)
Options and warrants lapsed/expired	(361,861)	(368,000)
Options and warrants lapsed/expired			(2,251,320)
Remeasurement of options issued in prior period			(607,000)
Balance	3,166,419	3,466,642	1,133,345
Currency translation differences	6,708	(14,953)	102,938
Share-based payments [Member]
Other Reserves (Details) - Schedule of other reserves [Line Items]
Balance	3,360,128	1,011,878	4,281,790
Other comprehensive income
Share-based payment expenses			73,088
Transfer to share capital		(73,088)
Options and warrants issued/expensed	54,930	3,003,060	(484,680)
Options and warrants exercised		(213,722)
Options and warrants lapsed/expired	(361,861)	(368,000)
Options and warrants lapsed/expired			(2,251,320)
Remeasurement of options issued in prior period			(607,000)
Balance	3,053,197	3,360,128	1,011,878
Currency translation differences
Foreign currency translation [Member]
Other Reserves (Details) - Schedule of other reserves [Line Items]
Balance	106,514	121,467	18,529
Other comprehensive income	6,708	(14,953)	102,938
Share-based payment expenses
Transfer to share capital
Options and warrants issued/expensed
Options and warrants exercised
Options and warrants lapsed/expired
Options and warrants lapsed/expired
Remeasurement of options issued in prior period
Balance	113,222	106,514	121,467
Currency translation differences	$ 6,708	$ (14,953)	$ 102,938

Other Reserves (Details) - Sc_2

Other Reserves (Details) - Schedule of movements in options and warrants $ in Millions	12 Months Ended
	Jun. 30, 2022 AUD ($) shares	Jun. 30, 2021 AUD ($) shares	Jun. 30, 2020 AUD ($) shares	Jun. 30, 2020 USD ($) shares
Schedule Of Movements In Options And Warrants Abstract
Balance | shares	45,309,478	42,807,118	79,463,744	79,463,744
Balance (in Dollars)	$ 3,360,128	$ 1,011,878	$ 4,281,790
Balance | shares	19,873,877	45,309,478	42,807,118	42,807,118
Balance (in Dollars)	$ 3,053,197	$ 3,360,128	$ 1,011,878
Remeasurement of options issued in prior period (2019-11-06) | shares
Remeasurement of options issued in prior period (2019-11-06) (in Dollars)			$ (607,000)
Issue of representative warrants (2019-07-16) | shares			542,600	542,600
Issue of representative warrants (2019-07-16) (in Dollars)			$ 55,454
Lapse of unexercised options at $0.50 (2019-11-27) | shares			(7,625,532)	(7,625,532)
Lapse of unexercised options at $0.50 (2019-11-27) (in Dollars)			$ (2,086,920)
Lapse of unexercised options at $0.55 (2019-11-30) | shares			(25,289,894)	(25,289,894)
Lapse of unexercised options at $0.55 (2019-11-30) (in Dollars)
Lapse of unexercised options at $0.50 (2020-06-30) | shares			(2,000,000)	(2,000,000)
Lapse of unexercised options at $0.50 (2020-06-30) (in Dollars)			$ (164,400)
Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23) | shares			(218,800)	(218,800)
Exercise of NASDAQ Warrants at US$10 per 40 options (2020-06-23) (in Dollars)			$ (72)
Exercise of representative warrants (2020-06-15, 2020-06-22) | shares			(2,065,000)	(2,065,000)
Exercise of representative warrants (2020-06-15, 2020-06-22) (in Dollars)			$ (540,062)
Share-based payments expenses (in Dollars)				$ 73,088
Exercise of representative warrants (2020-07-2) | shares		(9,640)
Exercise of representative warrants (2020-07-2) (in Dollars)
Exercise of ESOP unlisted options at $0.50 (2020-07-24) | shares		(100,000)
Exercise of ESOP unlisted options at $0.50 (2020-07-24) (in Dollars)		$ (15,700)
Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29) | shares		(3,048,000)
Exercise of NASDAQ Warrants at US$10 per 40 options (2020-07-27, 2020-07-29) (in Dollars)		$ (1,012)
Lapse of unexercised options (2020-09-25) | shares		(5,000,000)
Lapse of unexercised options (2020-09-25) (in Dollars)		$ (368,000)
Issue of representative warrants at US$23.44 per 40 options (2020-07-24) | shares		2,560,000
Issue of representative warrants at US$23.44 per 40 options (2020-07-24) (in Dollars)		$ 1,032,960
Issue of ESOP unlisted options at $0.12 (2020-10-29) | shares		9,000,000
Issue of ESOP unlisted options at $0.12 (2020-10-29) (in Dollars)		$ 1,970,100
Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09) | shares		(900,000)
Cashless exercise of ESOP unlisted options at $0.12 (2021-02-09) (in Dollars)		$ (197,010)
Reclassify share-based payments expenses from reserves to share capital | shares
Reclassify share-based payments expenses from reserves to share capital (in Dollars)		$ (73,088)
Lapse of unexercised options at $0.50 (2021-07-01) | shares	(1,200,000)
Lapse of unexercised options at $0.50 (2021-07-01) (in Dollars)	$ (188,400)
Issue of ESOP unlisted options at $0.25 (2021-11-05) | shares	500,000
Issue of ESOP unlisted options at $0.25 (2021-11-05) (in Dollars)	$ 18,624
Lapse of unexercised options at $1.94 (2021-11-30) | shares	(14,493)
Lapse of unexercised options at $1.94 (2021-11-30) (in Dollars)	$ (28,813)
Lapse of unexercised options at $1.94 (2022-06-14) | shares	(24,721,108)
Lapse of unexercised options at $1.94 (2022-06-14) (in Dollars)	$ (144,648)
ESOP unlisted options granted at $0.12 (2022-06-27) | shares
ESOP unlisted options granted at $0.12 (2022-06-27) (in Dollars)	$ 36,306

Segment Reporting (Details)

Segment Reporting (Details)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Entitys Operating Segments Text Block Abstract
Number of segment	2
Percentage of total revenue for major customer	10%	10%	10%

Segment Reporting (Details) - S

Segment Reporting (Details) - Schedule of segment information for the reportable segments - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]
Hyperimmune products revenue	$ 765,193	$ 145,776	$ 2,518,566
Cost of sales of goods	(241,691)	(51,071)	(688,836)
Gross profit	523,502	94,705	1,829,730
Other income	957,725	617,110	473,674
Net foreign exchange gains/(losses)	247,558	(582,528)	11,335
Net impairment losses		(759,765)
General and administrative expenses	(3,524,388)	(6,094,692)	(3,170,078)
Research and development expenses	(657,715)	(1,367,054)	(1,178,685)
Selling and marketing expenses	(416,537)	(287,684)	(871,551)
Operating profit/(loss)	(2,869,855)	(8,379,908)	(2,905,575)
Finance income	21,785	9,204
Finance costs	(6,184)	(13,761)	(21,631)
Income tax expense
Profit/(loss) for the year	(2,854,254)	(8,384,465)	(2,927,206)
Assets
Segment assets	24,855,824	27,053,106	6,202,163
Total assets	24,855,824	27,053,106	6,202,163
Liabilities
Segment liabilities	1,678,423	1,158,049	558,250
Total liabilities	1,678,423	1,158,049	558,250
Research and development [Member]
Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]
Hyperimmune products revenue
Cost of sales of goods
Gross profit
Other income	933,140	431,030	308,225
Net foreign exchange gains/(losses)
General and administrative expenses
Research and development expenses	(657,715)	(1,367,054)	(1,178,685)
Selling and marketing expenses
Operating profit/(loss)	275,425	(936,024)	(870,460)
Finance income
Finance costs
Income tax expense
Profit/(loss) for the year	275,425	(936,024)	(870,460)
Assets
Segment assets	257,500	306,154	308,225
Total assets	257,500	306,154	308,225
Liabilities
Segment liabilities	7,053	243,565	101,092
Total liabilities	7,053	243,565	101,092
Hyperimmune products [Member]
Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]
Hyperimmune products revenue	765,193	145,776	2,518,566
Cost of sales of goods	(241,691)	(51,071)	(688,836)
Gross profit	523,502	94,705	1,829,730
Other income	24,585	24,480	10,545
Net foreign exchange gains/(losses)
Net impairment losses		(759,765)
General and administrative expenses	(164,087)
Research and development expenses
Selling and marketing expenses	(416,537)	(287,684)	(871,551)
Operating profit/(loss)	(32,537)	(928,264)	968,724
Finance income
Finance costs
Income tax expense
Profit/(loss) for the year	(32,537)	(928,264)	968,724
Assets
Segment assets	1,688,910	1,587,672	2,539,503
Total assets	1,688,910	1,587,672	2,539,503
Liabilities
Segment liabilities	150,151	284,657	30,377
Total liabilities	150,151	284,657	30,377
Other [Member]
Segment Reporting (Details) - Schedule of segment information for the reportable segments [Line Items]
Hyperimmune products revenue
Cost of sales of goods
Gross profit
Other income		161,600	154,904
Net foreign exchange gains/(losses)	247,558	(582,528)	11,335
General and administrative expenses	(3,360,301)	(6,094,692)	(3,170,078)
Research and development expenses
Selling and marketing expenses
Operating profit/(loss)	(3,112,743)	(6,515,620)	(3,003,839)
Finance income	21,785	9,204
Finance costs	(6,184)	(13,761)	(21,631)
Income tax expense
Profit/(loss) for the year	(3,097,142)	(6,520,177)	(3,025,470)
Assets
Segment assets	22,909,414	25,159,280	3,354,435
Total assets	22,909,414	25,159,280	3,354,435
Liabilities
Segment liabilities	1,521,219	629,827	426,781
Total liabilities	$ 1,521,219	$ 629,827	$ 426,781

Segment Reporting (Details) -_2

Segment Reporting (Details) - Schedule of information on geographical regions - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2020
Travelan [Member] | Australia [Member]
Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]
Hyperimmune products revenue	$ 143,378	$ (10,308)	[1]	$ 1,240,393
Revenue from external customers	143,378	(10,308)		1,240,393
Travelan [Member] | United States [Member]
Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]
Hyperimmune products revenue	501,228	4,264	[1]	926,325
Revenue from external customers	501,228	4,264		926,325
Travelan [Member] | Other [Member]
Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]
Hyperimmune products revenue	63,172	101,639	[1]	301,915
Revenue from external customers	63,172	101,639		301,915
Protectyn [Member] | Australia [Member]
Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]
Hyperimmune products revenue	57,415	50,181	[1]	49,933
Revenue from external customers	57,415	50,181		49,933
Protectyn [Member] | Other [Member]
Segment Reporting (Details) - Schedule of information on geographical regions [Line Items]
Hyperimmune products revenue	765,193	145,776	[1]	2,518,566
Revenue from external customers	$ 765,193	$ 145,776		$ 2,518,566
[1]Returns are provided where outlined in a customer’s agreement.

Segment Reporting (Details) -_3

Segment Reporting (Details) - Schedule of major customers - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers	$ 616,732	$ 140,022	$ 1,898,982
Customer A [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers	263,137		327,559
Customer B [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers	253,803	23,214	462,490
Customer C [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers	$ 99,792		438,065
Customer D [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers			442,916
Customer E [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers			$ 227,952
Customer F [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers		41,040
Customer G [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers		27,563
Customer H [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers		25,319
Customer I [Member]
Segment Reporting (Details) - Schedule of major customers [Line Items]
Total revenue for major customers		$ 22,886

Cash Flow Information (Details)

Cash Flow Information (Details) - Schedule of reconciliation of cash flow from operations with loss after income tax - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Schedule Of Reconciliation Of Cash Flow From Operations With Loss After Income Tax Abstract
Net Loss for the Year	$ (2,854,254)	$ (8,384,465)	$ (2,927,206)
Adjustments for
Depreciation expense	26,613	43,662	44,056
Lease modification	15,993
Distribution costs	35,000		70,000
Expected credit losses	8,809	(30,055)	(3,991)
Finance costs	6,184	13,761	21,631
Finance income	(21,785)	(9,204)
Leave provision expense	45,470	53,610	19,717
Share-based payments (income)/expenses	94,891	2,116,013	(533,912)
Unrealized net foreign currency gains	(234,794)	592,243	(18,883)
Change in operating assets and liabilities:
Add decrease in trade and other receivables	(336,998)	23,037	641,236
Add (increase) / decrease in inventories	275,605	960,920	(113,635)
Add (increase) / decrease in other operating assets	(494,143)	(45,065)	16,096
Add (decrease) / increase in trade and other payables	285,616	586,796	(362,437)
Total	$ (3,147,793)	$ (4,078,747)	$ (3,147,328)

Share-based Payments (Details)

Share-based Payments (Details) - USD ($)		12 Months Ended
	Jun. 27, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Share Based Payment Arrangements Text Block Abstract
Options granted (in Dollars per share)	$ 1,430,000
Option granted, description		Options granted to a former managing director on 11 February 2019 and valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a remeasurement of $607,000 in the 30 June 2020 financials.
Shares issued to directors for the director fees			$ 145,913	$ 73,088

Share-based Payments (Details)

Share-based Payments (Details) - Schedule of movement in number of stock options outstanding and weighted average exercise price	12 Months Ended
	Jun. 30, 2022 $ / shares $ / shares shares	Jun. 30, 2021 $ / shares $ / shares shares	Jun. 30, 2020 $ / shares $ / shares shares
Schedule Of Movement In Number Of Stock Options Outstanding And Weighted Average Exercise Price Abstract
Average exercise price per share option, As at 1 July (in Dollars per share) | $ / shares	$ 0.31	$ 0.4	$ 0.46
Number of options, As at 1 July | shares	45,309,478	42,807,118	79,463,744
Average exercise price per share option, Granted during the year (in Dollars per share) | $ / shares	$ 0.25	$ 0.28	$ 0.18
Number of options, Granted during the year | shares	500,000	11,560,000	542,600
Average exercise price per share option, Exercised during the year (in Dollars per share) | $ / shares		$ 0.23	$ 0.18
Number of options, Exercised during the year | shares		(4,057,640)	(424,840)
Average exercise price per share option, Forfeited/lapsed during the year (in Dollars per share) | $ / shares	$ 0.27	$ 0.5	$ 0.52
Number of options,Forfeited/lapsed during the year | shares	(25,935,601)	(5,000,000)	(36,774,386)
Average exercise price per share option, As at 30 June (in Dollars per share) | $ / shares	$ 0.37	$ 0.31	$ 0.4
Number of options, As at 30 June | shares	19,873,877	45,309,478	42,807,118
Average exercise price per share option, Vested and exercisable at 30 June (in Dollars per share) | $ / shares	$ 0.37	$ 0.31	$ 0.4
Number of options,Vested and exercisable at 30 June | shares	19,538,877	45,309,478	42,807,118

Share-based Payments (Details_2

Share-based Payments (Details) - Schedule of share options outstanding - $ / shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Share options	19,873,877	45,309,478	42,807,118
Share options price per share	$ 1.54	$ 1.58	$ 2.28
2012-06-29 [Member]
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Expiry date	Nov. 30, 2021
Exercise price	1.944
Share options		14,493	14,493
2012-06-29 [Member]
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Expiry date	Jan. 17, 2022
Exercise price	1.876
Share options		29,668	29,668
2017-06-13 (warrants) [Member]
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Expiry date	Jun. 13, 2022
Exercise price	0.25
Share options		24,493,200	27,541,200
2018-03-15 [Member]
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Expiry date	Mar. 15, 2023
Exercise price	0.468
Share options	7,897,647	7,897,647	7,897,647
2017-06-09 (warrants) [Member]
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Expiry date	Jun. 08, 2022
Exercise price	0.3125
Share options		198,240	198,240
2018-03-15 [Member]
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Expiry date	Mar. 15, 2023
Exercise price	0.585
Share options	526,510	526,510	526,510
2019-05-23 (warrants) [Member]
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Expiry date	May 23, 2024
Exercise price	0.125
Share options	173,600	173,600	181,600
2019-07-16 (warrants) [Member]
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Expiry date	Jul. 16, 2024
Exercise price	0.125
Share options	116,120	116,120	117,760
2018-07-13 [Member]
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Expiry date	Jul. 01, 2021
Exercise price	0.500
Share options		1,200,000	1,300,000
2019-11-06 [Member]
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Expiry date	Feb. 10, 2024
Exercise price	0.500
Share options			5,000,000
2020-10-29 [Member]
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Expiry date	Apr. 14, 2024
Exercise price	0.12
Share options	8,100,000	8,100,000
2020-07-24 (warrants) [Member]
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Expiry date	Jul. 21, 2025
Exercise price	0.5859
Share options	2,560,000	2,560,000
2021-10-26 [Member]
Share-based Payments (Details) - Schedule of share options outstanding [Line Items]
Expiry date	Oct. 26, 2025
Exercise price	0.25
Share options	500,000

Share-based Payments (Details_3

Share-based Payments (Details) - Schedule of granted valuation of options - $ / shares	12 Months Ended
	Jun. 30, 2022		Jun. 30, 2021	Jun. 30, 2020
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
No. of options (in Dollars per share)	$ 1,930,000		$ 11,560,000	$ 5,000,000
Exercise Price One [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	Oct. 26, 2025		Jul. 21, 2025	Feb. 10, 2024
Exercise price	0.25		0.83	0.50
No. of options (in Dollars per share)	$ 500,000		$ 2,560,000	$ 5,000,000	[1]
Share price at grant date (in Shares)	0.12		0.5	0.15
Expected volatility	131.70%		127.93%	98%
Dividend yield	0%		0%	0%
Risk- free interest rate	0.69%		0.43%	0.88%
Fair value at grant date per option (in Dollars per share)	$ 0.0886		$ 0.4035	$ 0.0736
Exercise Price Two [Member]
Share-based Payments (Details) - Schedule of granted valuation of options [Line Items]
Expiry date	Jun. 27, 2026		Apr. 14, 2024
Exercise price	0.12		0.12
No. of options (in Dollars per share)	$ 1,430,000	[2]	$ 9,000,000
Share price at grant date (in Shares)	0.07		0.25
Expected volatility	128.10%		142.70%
Dividend yield	0%		0%
Risk- free interest rate	3.31%		0.13%
Fair value at grant date per option (in Dollars per share)	$ 0.053		$ 0.2189
[1]Options issued to a former managing director expire within 6 months upon his resignation on 25 March 2020 without good reason or termination.[2]1,430,000 options granted to Mr. Lydeamore on 27 June 2022 and subsequently issued after the reporting period, on 1 July 2022.

Share-based Payments (Details_4

Share-based Payments (Details) - Schedule of total expenses arising from share-based payment transactions - AUD ($)		12 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	[1]
Schedule Of Total Expenses Arising From Share Based Payment Transactions Abstract
Options issued under OIP		$ 54,930	$ 1,970,100	$ (607,000)
Shares issued under OIP		39,960
Share-based payments to KMP	[2]		145,913	73,088
Total		$ 94,890	$ 2,116,013	$ (533,912)
[1]Options granted to a former managing director on 11 February 2019 and valued at $975,000 in the 30 June 2019 financials were subject to shareholder approval. In line with IFRS 2, these were re-measured at grant date 6 November 2019 after being approved by shareholders with a value of $368,000, being a remeasurement of $607,000 in the 30 June 2020 financials.[2]Due to the ongoing crisis of COVID-19, the groups directors decided to forgo cash payments of their director fees and instead receive shares of that value. As at 30 June 2021, shares have been issued to directors for the director fees of $145,913 incurred during the financial year ended 30 June 2021 and $73,088 incurred during the financial year ended 30 June 2020, given the shareholders’ approval at the AGM held on 29 October 2020.

Related Party Transactions (Det

Related Party Transactions (Details)				1 Months Ended	12 Months Ended
	Jul. 01, 2021 AUD ($)	Jul. 01, 2020 USD ($)	Jan. 01, 2019 AUD ($)	Jan. 31, 2017 AUD ($)	Jun. 30, 2022 AUD ($) $ / shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021 AUD ($)	Jun. 30, 2020 AUD ($) shares	Jun. 30, 2019 AUD ($) shares
Related Party Transactions (Details) [Line Items]
Rental expense					$ 42,990
Lease renewed					Jan. 01, 2022	Jan. 01, 2022
Additional payable					$ 35,000
Legal services (in Dollars)						$ 20,000
Wattle Laboratories Pty Ltd [Member]
Related Party Transactions (Details) [Line Items]
Rental expense			$ 41,738		42,364		$ 40,607	$ 41,369
Wattle Laboratories Pty Ltd [Member] | Short-term Funding Agreements [Member]
Related Party Transactions (Details) [Line Items]
Rental expense				$ 39,525
Grandlodge Capital Pty Ltd [Member]
Related Party Transactions (Details) [Line Items]
Warehousing, distribution and invoicing services	$ 77,000	$ 70,000			$ 70,000
Share issued price per share (in Dollars per share) | $ / shares					$ 0.16
Warehousing distribution and services fees								$ 100,978	$ 93,678
Ordinary shares issued (in Shares) | shares								437,500	437,500

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of information about other related party transactions - AUD ($)		12 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Related Party Transactions (Details) - Schedule of information about other related party transactions [Line Items]
Purchases of various goods and services from entities controlled by key management personnel	[1]	$ 154,364	$ 110,607	$ 142,347
Other transactions with key management personnel		154,364	110,607	142,347
Legal services by key management personnel	[2]	20,000
Rental of an office suite from Wattle Laboratories Pty Ltd [Member]
Related Party Transactions (Details) - Schedule of information about other related party transactions [Line Items]
Other transactions with key management personnel		42,364	40,607	41,369
Services rendered by Grandlodge Capital Pty Ltd [Member]
Related Party Transactions (Details) - Schedule of information about other related party transactions [Line Items]
Other transactions with key management personnel		$ 112,000	$ 70,000	$ 100,978
[1]Purchases from entities controlled by key management personnel[2]Legal services by key management personnel

Related Party Transactions (D_3

Related Party Transactions (Details) - Schedule of outstanding balances transactions with related parties - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Current payables (purchases of goods and services)
Entities controlled by key management personnel	$ 77,000	$ 70,000

Financial Risk Management Obj_3

Financial Risk Management Objectives and Policies (Details)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Financial Risk Management Text Block Abstract
Percentage of USD/AUD exchange rate	5.80%	4.90%

Financial Risk Management Obj_4

Financial Risk Management Objectives and Policies (Details) - Schedule of foreign currency risk	Jun. 30, 2022 USD ($)	Jun. 30, 2022 CAD ($)	Jun. 30, 2022 ILS (₪)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 CAD ($)	Jun. 30, 2021 ILS (₪)
Schedule Of Foreign Currency Risk Abstract
Cash and cash equivalents	$ 3,138,079	$ 29,224		$ 2,742,688	$ 108,688
Trade receivables	279,986			23,801
Trade payables	73,430	803	2,240	18,556	43,466
Total exposure	$ 3,491,495	$ 30,027	₪ 2,240	$ 2,785,045	$ 152,154

Financial Risk Management Obj_5

Financial Risk Management Objectives and Policies (Details) - Schedule of exchange rates - AUD ($)	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Exchange Rates Abstract
Impact on loss for the period	$ 202,507	$ 136,467
Impact on other components of equity	$ 6,567	$ 5,219

Financial Risk Management Obj_6

Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables - AUD ($)	Jun. 30, 2022	Jun. 30, 2021
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate
Gross carrying amount	$ 8,809	$ 28,553
Loss allowance
Current [member]
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate	0%	0%
Gross carrying amount		$ 23,801
Loss allowance
1-30 [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate	0%	0%
Gross carrying amount		$ 4,752
Loss allowance
31-60 [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate	13.08%	13.07%
Gross carrying amount	$ 7,959
Loss allowance
61-90 [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate	24.14%	21.88%
Gross carrying amount	$ 664
Loss allowance
91-120 [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate	26.84%	34.09%
Gross carrying amount	$ 186
Loss allowance
121+ [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of trade receivables [Line Items]
Expected credit loss rate	0%	53.58%
Gross carrying amount
Loss allowance

Financial Risk Management Obj_7

Financial Risk Management Objectives and Policies (Details) - Schedule of contractual discounted cash flows - AUD ($)	Jun. 30, 2022	Jun. 30, 2021
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual discounted cash flows [Line Items]
Trade and other payables	$ 748,980	$ 132,514
Lease liabilities	34,376	20,498
Total	748,980	153,012
Less than 6 months [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual discounted cash flows [Line Items]
Trade and other payables	748,980	132,514
Lease liabilities	34,376	20,498
Total	748,980	153,012
Total contractual cash flows [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual discounted cash flows [Line Items]
Trade and other payables	748,980	132,514
Lease liabilities	34,376	20,498
Total	748,980	153,012
6 - 12 months [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual discounted cash flows [Line Items]
Trade and other payables
Lease liabilities
Total
Between 1 and 2 years [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual discounted cash flows [Line Items]
Trade and other payables
Lease liabilities
Total
Between 2 and 5 years [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual discounted cash flows [Line Items]
Trade and other payables
Lease liabilities
Total
Over 5 years [Member]
Financial Risk Management Objectives and Policies (Details) - Schedule of contractual discounted cash flows [Line Items]
Trade and other payables
Lease liabilities
Total

Parent Entity Financial Infor_3

Parent Entity Financial Information (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Parent Entity Financial Information Abstract
Debt

Parent Entity Financial Infor_4

Parent Entity Financial Information (Details) - Schedule of individual financial statements for the parent entity - Parent Company [Member] - USD ($)	12 Months Ended
	May 31, 2022	May 31, 2021
Condensed Financial Statements, Captions [Line Items]
Current assets	$ 23,685,902	$ 25,698,082
Non-current assets	1,181,517	1,300,467
Total assets	24,867,419	26,998,549
Current liabilities	1,498,834	1,118,020
Non-current liabilities	175,447	36,196
Total liabilities	1,674,281	1,154,216
Total	(46,386,276)	(51,688,666)
Share capital	88,436,263	88,361,303
Share-based payments	3,053,197	3,360,128
Accumulated losses	(68,296,322)	(65,877,098)
Total Shareholders' equity	23,193,138	25,844,333
Loss for the year	2,781,085	8,271,111
Total comprehensive loss	$ 2,781,085	$ 8,271,111

Auditors' Remuneration (Details

Auditors' Remuneration (Details) - Schedule of auditors' remuneration for each of the years indicated, the fees billed by Grant Thornton Audit Pty Ltd - AUD ($)		12 Months Ended
		Jun. 30, 2022	Jun. 30, 2021
Schedule Of Auditors Remuneration For Each Of The Years Indicated The Fees Billed By Grant Thornton Audit Pty Ltd Abstract
Audit and review of financial statements	[1]	$ 173,631	$ 179,742
Total		$ 173,631	$ 179,742
[1] Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant can reasonably provide.